About STCS research

STCS projects

FUP
number

Approval
date

Title

Status

FUP278

2026-09-07

Prevalence and Evolution of Self-Reported Sun Exposure and Adherence to Sun Protective Behaviours and Its Impact on Squamous Cell Carcinoma and Basal Cell Carcinoma Incidence in the First 10 Years Post-Solid Organ Transplantation: The Swiss Transplant Cohort Study (STCS)

Acceptance

Investigator

Soroush Veisi

Project summary

Background

For selected patients with end-stage organ failure, organ transplant is a major therapeutic procedure. Despite therapeutic advances, recipient of solid organ transplant (SOTRs) remain at significantly elevated risk for chronic complications, among which malignancies represent a major contributor to morbidity and mortality. Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most frequently occurring malignancies in this population. The incidence of SCC and BCC varies widely across regions, reflecting differences in ultraviolet (UV) radiation exposure and individual characteristics. Howe ever, ultraviolet radiation remains the most important modifiable risk factor. One of the most effective and widely recommended strategies for reducing skin cancer risk is consistent adherence to sun protective behaviours, including regular sunscreen use, wearing protective clothing, and minimizing sun exposure during peak hours. Quantitative evidence demonstrates considerable variability in recommended protective measures and overall low adherence, while behavioural studies show that adherence is dynamic, evolving over time and often following episodic patterns. To date, the behaviour of patients with SCC and BCC regarding sun protection and sun exposure over time has not been well described, as most studies are cross-sectional, resulting in limited evidence and a substantial gap in longitudinal data. Furthermore, this study aims to strengthen the assessment of self-reported behaviours by linking them to objective clinical outcomes, namely the of keratinocyte carcinoma. Understanding the prevalence and evolution of sun protection behaviours, as well as their impact on the incidence of SCC and BCC, addresses therefore an important knowledge gap in the transplant literature.

Study aims

1. To evaluate the prevalence and evolution of self-reported sun exposure and adherence to sun protective behaviours in adult organ transplant recipients 10 years after Tx. 2. To evaluate the impact of self-reported sun exposure and adherence to sun protective behaviours on the incidence of new-onset SCC or new-onset BCC in adult organ transplant recipients 10 years after Tx.

Study design

This study is a secondary analysis of the Swiss Transplant Cohort Study (STCS) (17), STCS is a nationwide open cohort study, including transplant recipients from all six Swiss transplant centres, namely the five University Hospitals in Basel, Bern, Geneva, Lausanne, and Zurich, as well as the Cantonal Hospital of St. Gallen. The STCS provides comprehensive coverage of solid organ transplantation in Switzerland with long-term follow-up (18). All adult patients enrolled in the STCS who have undergone kidney, liver, lung, or heart transplantation will be considered. The STCS has enrolled SOTRs since May 2008 and systematically collects longitudinal clinical, psychosocial, behavioural, quality of life, and genetic data at predefined follow-up time points. The study includes sun exposure and sun-protective behaviours, as well as psychosocial, behavioural, demographic, and clinical variables obtained from the Psychosocial Questionnaire (PSQ) (19), the STCS database, and additional relevant sociodemographic and clinical characteristic items. Incidence of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) after transplantation will be measured using STCS und PSQ clinical records and will be evaluated during the first 10 years post-transplantation.

Lay summary

Descriptive title

How Sun Protection Behaviours Change Over Time, Why They Matter, and How They Affect Skin Cancer Risk After Transplant

Main goals

This study looks at how people protect their skin from the sun after receiving an organ transplant. It examines how sun exposure and sun protective habits change during the first 10 years after transplantation. The study also investigates whether not following sun protection advice increases the risk of developing common types of skin cancer.

Why of interest

Organ transplantation saves lives and allows many people to live longer and healthier. However, transplant recipients need to take lifelong medication to prevent rejection of the transplanted organ. These medications weaken the immune system and increase the risk of cancers. Skin cancer is the most common cancer in organ recipient. The risk is much higher than in the general population, and it increases over time. Sun exposure is the most important risk factor that patients can control. Studies recommend simple protective measures such as using sunscreen with a high protection factor, wearing protective clothing, avoiding strong midday sun, and staying in the shade. However, many transplant patients do not follow this advice regularly. Some may forget, find it inconvenient, or underestimate their personal risk. At the same time, little is known about how these habits change over time or how strongly they affect the development of skin cancer.

Expected benefit

This study will improve understanding of how sun protection habits develop over time after transplantation and how they relate to skin cancer risk. The results may help healthcare professionals design better education and prevention programs tailored to transplant patients. In the long term, this research could support earlier and more targeted interventions, reduce the number of skin cancer cases, and improve the long-term health and quality of life of transplant recipients.

FUP279

2026-08-19

Effects of arteriovenous fistula (vascular access) failure on kidney graft outcome: a prospective study

Acceptance

Investigator

Pierre Barras

Project summary

Background

Kidney transplantation remains the treatment of choice for patients with end-stage kidney disease, offering superior survival and quality of life compared with dialysis. However, a large proportion of transplant candidates require hemodialysis prior to transplantation, most commonly through an arteriovenous fistula (AVF). While AVFs are essential for providing reliable dialysis access, evidence regarding their potential impact on graft outcomes after transplantation remains limited. Neither the European Best Practice Guidelines on Vascular Access1, the Kidney Disease Outcomes Quality Initiative2, nor the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on post-transplant care3 provide specific recommendations regarding whether AVFs should be preserved or closed after kidney transplantation. Although AVFs remain functional in most transplant recipients, both spontaneous failure and surgical closure are frequently observed4,6 The impact of AVF persistence versus closure on kidney graft function remains uncertain, as several previous studies have shown conflicting results (cf point 8.1).

Study aims

In this study, we aim to assess the impact of AVF patency and closure on graft function and outcomes in kidney transplant recipients enrolled in the Swiss Transplant Cohort Study, using prospectively collected data from 2008 to 2025.

Study design

The study is a monocenter prospective observational study including patients from Lausanne University Hospital. The study will use the prospectively collected clinical data available in the Swiss transplant cohort study (STCS), regarding the transplant recipient patient and the kidney graft. The ongoing prospective STCS has already been approved by the ethic commissions (EC) of canton de Vaud. All patients included in the STCS have already signed an informed consent.

Lay summary

Descriptive title

Prospective Study on the Impact of Arteriovenous Fistula (AVF) — Failure Surgical or Spontaneous —on Kidney Graft Outcomes

Main goals

To evaluate the impact of AVF patency and AVF closure (spontaneous thrombosis or elective surgical ligation) on graft function and long-term outcomes in kidney transplant recipients. Whether persistent AVF patency influences kidney graft function after transplantation remains uncertain.

Why of interest

Previous studies have reported conflicting results, and, to our knowledge, no prospective study has specifically assessed the long-term (>5 years) impact of AVF closure on graft outcomes. This study addresses a highly relevant clinical question, as a substantial proportion of kidney transplant recipients retain a functioning AVF. Decisions regarding routine AVF surveillance (e.g., by Doppler ultrasound), attempts to salvage a fistula in case of suspected spontaneous thrombosis, or elective surgical ligation at the patient’s request are part of everyday clinical practice in transplantation centers and nephrology clinics.

Expected benefit

Clarifying the long-term consequences of AVF patency versus closure on graft function will provide evidence-based guidance for these common management dilemmas and may directly benefit transplant recipients.

FUP281

2026-09-02

Prevalence of multidrug resistant microorganism infection among solid organ transplant recipients

Acceptance

Investigator

Laura Naëmi Walti

Project summary

Background

Patients undergoing solid organ transplantation are at increased risk for infections caused by multidrug-resistant organisms (MDROs), which significantly impact both patient and graft survival. Different MDRO pathogens (e.g.; vancomycin-resistant Enterococcus (VRE), ESBL-Enterobacterales, carbapnem-resistant or carbapnemase-producing Enterobacterales and - Pseudomonas (CRE or CPE) as well as carbapenem-resistant Acinetobacter baumannii (CRAB) have been associateted with high mortality rates. Despite this potential impact on SOT outcome there are few studies addressing these microorganism in the transplant scenario, and more important in part of the SOT centers the knowledge of the prevalence of those infections in this population is absent which is clearly the first step to design effective control strategies. Moreover, literature on MDROs in low- and middle-income countries is relatively scarce, despite around 40% of transplants beeing performed in LMICs (e.g. China, India and Brazil). Additionally, the movement of SOT recipients and even organs across borders underscores the importance of understanding the global distribution of MDROs. This knowledge is crucial not only for preventive measures but also to assist clinicians in assessing risk and guiding empirical therapy. Therefore, the aim of this study is to describe the prevalence and distribution of MDRO infections in solid organ transplant recipients through an international multicenter study, including centers in both HICs and LMICs.

Study aims

The aim of this study is to estimate the global incidence of bloodstream infections caused by MDROs in SOT recipients transplanted in 2024, categorized by organ type, microorgansim and carbapenemase production.

Study design

This study will be a multicenter, international, cross-sectional study involving transplant centers from around the world. Data will be collected via an electronic questionnaire using the REDCap platform. Each center will provide data covering a 12-month period for patients undergoing solid organ transplantation (SOT) between January 2024 and December 2024, with at least six months of follow-up post-transplant or less if the patient dies. The data collection will include: • The number of transplant procedures performed during this period, categorized by organ type. • Regarding infections among transplant recipients during the period: o The number of bloodstream infections (BSI), categorized by organ type. o The number of BSIs due to MDROs in SOT recipients, categorized by organ type, microorganism and carbapenemase producing.

Lay summary

Descriptive title

Frequency of multidrug resistant microorganism infection among solid organ transplant recipients

Main goals

The main goal of this study is to report how frequent multi-drug resistant bacteria are found in bloodstream infections in the first 6 months post-transplant around the world. The frequency will be described in patients with different organ transplant (e.g. kidney, heart, lung and liver) because frequencies can differ according to the transplanted organ.

Why of interest

To understand the contribution of multi-drug resistant organisms in the transplant community is important to ensure appropriate antimicrobial treatment. Event if in Switzerland multi-drug resistant bacterial infections are still infrequent, patients eventually travel to areas with higher resistance rates. Therefore, this information is also of importance for domestic transplant recipients.

Expected benefit

This study offers to provide data on how frequent multi-drug resistant bacteria are found in blood stream infections early after transplantation. Further, these results will tell us if we should change empirical treatment (treatment given at the start of infection before we definitively know the bacteria involved). This is important to ensure adequate treatment, since inadequate treatment can lead to worse outcomes.

FUP280

2026-09-02

Emulative Target Trial on Antifungal Prophylaxis in Lung Transplant Recipients

Acceptance

Investigator

Laura Naëmi Walti

Project summary

Background

Invasive fungal infections (IFI), particularly invasive aspergillosis (IA), pose a major threat to lung transplant recipients due to immunosuppression, exposure to environmental fungal spores, and airway colonization. Existing antifungal prophylaxis strategies include universal prophylaxis, where all lung transplant recipients receive antifungal medications, and pre-emptive therapy, where antifungal treatment is initiated based on specific risk markers such as positive cultures or biomarker detection. Both strategies have potential disadvantages including drug toxicity, increased resistance, and unnecessary exposure for universal prophylaxis and risks missing early infections, potentially leading to poorer outcomes in preetmtive approaches. Despite several observational studies and small-scale trials, there remains no consensus on the most effective antifungal prophylaxis strategy in lung transplant recipients. Therefore, a robust observational study designed as an emulated target trial can provide valuable insights while addressing potential biases inherent to non-randomized studies. This study aims to leverage real-world clinical data to estimate the causal impact of different antifungal prophylaxis strategies and guide future clinical decision-making. Emulative target trial design is a method that enables researchers to analyze observational data as if it were collected from a hypothetical randomized trial. By reconstructing a trial-like environment using retrospective data, we aim to generate robust evidence on the optimal antifungal strategy to minimize invasive fungal infections and improve post-transplant outcomes. Our findings will help inform clinical guidelines and enhance decision-making in lung transplantation medicine.

Study aims

This study aims to emulate a randomized controlled trial (RCT) using observational data to estimate the causal effect of antifungal prophylaxis strategies. Primary Objective: To compare the proportion of patients with probable or proven mold infection (tracheobronchitis, bronchial anastomosis infection, pulmonary or systemic fungal infection) at one-year post-transplant between universal prophylaxis and pre-emptive antifungal therapy. Secondary Objectives: 1. To assess the proportion of patients with mold colonization at one-year post-transplant. 2. To evaluate the rate of breakthrough fungal infection during prophylaxis. 3. To determine the time to develop mold colonization or invasive pulmonary infection. 4. To analyze mortality (all-cause and fungal infection-related) at one-year post-transplant. 5. To assess the use of empirical antifungals at one-year post-transplant. 6. To evaluate time to diagnosis of chronic lung allograft dysfunction (CLAD). 7. To assess resistance rates of Aspergillus and other resistant organisms. Exploratory Future Objective: To validate the machine learning models developed in the MARIA Study (REB: 22-5035), which assess the clinical risk factors for the development of Invasive Aspergillosis using sensitivity, specificity and area under the receiver operating curve (AUC).

Study design

Non-interventional, retrospective, target emulation trial comparing three groups: 1. Universal antifungal prophylaxis with inhaled amphotericin products. 2. Universal antifungal prophylaxis with mold-active azoles. 3. Pre-emptive therapy with azoles directed by positive BAL GM (>1.0) or Aspergillus culture/PCR without radiological or bronchoscopic evidence of disease.

Lay summary

Descriptive title

An international study to investigate antifungal prophlyaxis in lung transplant recipients.

Main goals

This study aims to understand which strategy for the prevention of fungal infections in lung transplant recipients is the most effective.

Why of interest

Lung transplant recipients have a high risk for invasive fungal infections. The risk is highest in the first year post-transplant. Currently two main strategies are used to try to minimize this risk: universal prophylaxis (giving antifungal treatment to all lung transplant recipients) and preemtive treatment (starting antifungal treatment only in the presence of certain risk factors (e.g. colonization of the airways with fungi)). To date it is unclear which approach is preferable. Both strategies have advantages and disadvantages. Universal prophylaxis namely, giving antifungals to all patients includes problems like drug costs and toxicity, could increase fungal resistance and exposure of patients who eventually would not need it. Pre-emptive therapy on the other hand could eventually lead to more frequent infections and eventually poorer outcomes.

Expected benefit

This study can eventually answer the question if all lung transplant recipients should receive antifungal prophlyaxis or if giving it only to selected patient at increased risk is the prefered approach. This information is important for both patients and professionals and will inform guidelines and help decision making in this vulnerable patient population.

FUP277

2026-07-02

Risk factors for recurrence of primary sclerosing cholangitis and graft loss: a retrospective cohort study in the Swiss Transplant Cohort

Acceptance

Investigator

Haniel Quintino

Project summary

Background

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive fibroinflammatory damage and stricturing of the intrahepatic and/or extrahepatic bile ducts, leading to biliary cirrhosis and end-stage liver disease. PSC predominantly affects young to middle-aged males and is strongly associated with inflammatory bowel disease (IBD) in up to 88% of cases, particularly ulcerative colitis. No medical therapy has been proven to alter disease progression or improve transplant-free survival, making liver transplantation the only definitive treatment. The primary indications for liver transplantation in PSC include decompensated cirrhosis with end-stage liver disease, recurrent bacterial cholangitis with sepsis, intractable pruritus, and in highly selected cases, early-stage cholangiocarcinoma. Despite excellent short-term outcomes following LT for PSC, with 5-year survival rates exceeding 80%, recurrent PSC (rPSC) in the allograft poses a substantial long-term challenge. Disease recurrence occurs in up to 10–37% of patients, significantly impacting graft survival and patient outcomes (1). The actuarial risks of recurrence is 15.6% at 5 years, 37.9% at 15 years, and up to 52.6% at 25 years. The median time to recurrence is approximately 2.3-8.9 years post- transplant. In pediatric populations, the incidence of recurrence appears higher, with rates of 10% at 2 years and 27% at 5 years following transplant (2). Long-term follow-up data shows cumulative incidence of 1.0% at 1 year, 8.0% at 5 years, 23.5% at 10 years, and 34.3% at 15 years (3).

Study aims

- Primary end point : incidence of rPSC in the Swiss cohort. - Secondary end point : pattern of recurrence and risk factors, with particular focus on modifiable perioperative and post-transplant factors (typer of IBD treatment at the era of biological therapies and immunosuppressive strategies).

Study design

Our study will be a Swiss multicentric observational study based on existing data. Data will be extracted from the recipient’s database of the Swiss Transplant Cohort Study (STCS) and from the Swiss Organ Allocation System (SOAS) database for donors and procurement data.

Lay summary

Descriptive title

Risk factors for recurrence of primary sclerosing cholangitis and graft loss: a retrospective cohort study in the Swiss Transplant Cohort

Main goals

The main goal of this study is to assess the epidemiology of rPSC in the Swiss setting as well as identifying risk factors for negative outcomes post-transplantation

Why of interest

Several studies have been made on the potential risk factors associated with rPSC and graft loss on patients who underwent liver transplantation for PSC. Our study aims to see if similar results can be found within the Swiss setting and to assess the epidemiology of rPSC or other post-LT negative outcomes in the Swiss cohort.

Expected benefit

Assessing the epidemiology of negative post-LT outcomes (especially rPSC) in the Swiss setting will help identify individuals at increased risk within the Swiss population, which may differ from other cohorts in terms of demographic characteristics and practices related to immunosuppression and IBD management and may support interventions targeting modifiable risk factors.

FUP276

2026-07-15

Impact of Resuscitation Measures on Organ Donation in Switzerland

Acceptance

Investigator

Gianna Bearth

Project summary

Background

Organ transplantation is one of the leading treatment options for end-stage organ failure, improving the survival rates and quality of life of transplant recipients (1). A previous analysis by Swisstransplant has evaluated the impact of cardiopulmonary resuscitation (CPR) on organ donation in Switzerland between 2016 and 2018 (2). The analysis of 461 deceased potential organ donors between 2016 and 2018 who underwent CPR represent a sizeable subgroup (37.5%) of all deceased organ donors in that period. Since the implementation of the nationwide donation after cardiocirculatory arrest in Switzerland in 2011 (3), the proportion of donors with anoxic brain damage is increasing (40% in 2022, 44% in 2025) (4). In addition to conventional resuscitation measures, extracorporeal membrane oxygenation (ECMO) is increasingly being used when haemodynamic stabilisation is not possible (5–9). With ECMO, patients who have had life-sustaining therapy withdrawn due to an unfavourable neurological prognosis or who have progressed to brain death may be considered controlled DCD type III or even DBD donors (8). A recent systematic review reports emerging evidence regarding organ donation from ECMO donors with high graft survival rates (10). However, there is only limited data available on this topic and further research is needed. Another system that is frequently used when haemodynamic stabilisation is not possible in cases of cardiogenic shock is the Impella (11). To our knowledge, no studies on organ donation in patients with an Impella device have been published.

Study aims

The primary aim of this project is to evaluate the evolution of the impact of CPR on organ donation and utilisation in Switzerland. To this end, we will compare baseline characteristics of deceased donors who underwent CPR (with or without ECMO) with those who did not, stratified by donor type (donation after brain death, DBD; donation after circulatory determination of death, DCD). This quality assurance project will assess the impact of CPR and CPR circumstances (e.g. reanimation time, in/out of hospital, lay/professional reanimation, ECMO usage, and no-flow durations) on donor and organ utilisation, as well as on organ yield during the period from 01.01.2022 to 31.12.2025. To date, there is only a limited amount of literature examining organ donation in ECMO donors. The aim of this study is therefore not only to investigate the impact of CPR between 2022 and 2025, but also, to examine the effects of advanced resuscitation measures, especially ECMO, on organ donation. Further, donors with an Impella device at the time of death are analysed. In addition, the study will assess the organ utilisation with 6 and 12-month graft survival (functional utilisation) using data from the Swiss Transplant Cohort Study STCS.

Study design

This retrospective study will include all donations from deceased donors in Switzerland between 1 January 2022 and 31 December 2025. Furthermore, transplant outcomes will be analysed for each donor, based on 6-month and 1-year graft and recipient survival rates. The donor and recipient data used for the project are from the SOAS and the STCS registries, respectively.

Lay summary

Descriptive title

Impact of Resuscitation Measures on Organ Donation in Switzerland - A Retrospective Analysis from 2022 to 2025

Main goals

Between 2016 and 2018 37.5% of deceased organ donors in Switzerland underwent resuscitation measures before organ donation. The aim of this study is to assess the evolution of the resuscitation measures in deceased organ donors between 01.01.2022 and 31.12.2025 and to examine the impact of resuscitation on organ donation. Furthermore, increasingly advanced measures are being used in resuscitation, such as the use of extracorporeal membrane oxygenation (ECMO), a technique involving the use of a heart-lung machine. Another relatively often used mechanical circulatory support device is the Impella, which is kind of a mechanical heart pump. The second goal of the study is to analyse the effects of these advanced resuscitation measures on organ donation. Finally, the effect of resuscitation and advanced resuscitation measures on 6-month and 1-year graft survival rates will be analysed

Why of interest

In recent years, there has been a remarkable increase in the number of organ donors who have undergone CPR. Furthermore, ECMO is becoming more frequently used when haemodynamic stabilisation is not possible. Patients in whom all resuscitation attempts have been unsuccessful may be eligible for organ donation. Given the ongoing shortage of organs donated for transplantation, it is important to examine the impact of CPR and ECMO on organ donation and transplant outcomes.

Expected benefit

The results will help transplant teams decide whether organs from patients who underwent unsuccessful reanimation (in particular with ECMO) are suitable organ donors for transplantation.

FUP273

2026-06-03

Postoperative infections in liver transplant recipients after DBD and DCD donation

Acceptance

Investigator

Stephanie Klinzing

Project summary

Background

Donation after Circulatory Death (DCD) was reintroduced in Switzerland in 2011 and accounts for a third of deceased organ donors today. As procurement and regimen differ for Donation after Brain Death (DBD) and DCD donation and DCD organs are exposed to warm ischemia time, it has been suggested that DBD and DCD grafts differ concerning postoperative complications and outcome. Recent studies report no differences between DBD and DCD Liver Transplantations (LT) regarding delayed graft function or early organ loss (Elmer et al. 2022). Also the single-centre study from Chen et al. conducted in China reports similar short- and long-term outcomes in LT from DCD donors compared to DBD donors (Chen et al. 2019). Whether there is a difference regarding early postoperative liver synthesis factors with focus on dynamics of factor V levels as well as differences in risk of infections between liver transplant recipients after DCD or DBD donations and whether the added warm ischemia time in DCD or differences in procurement contributes to an altered risk for infections remains unclear and is aimed to be clarified by this retrospective study. Early postoperative infections are a main complication after transplantation and contribute to mortality and morbidity. During the first year after LT over 75% of liver recipients will develop at least one infection (Ayvazoglu Soy et al. 2018). Leibovici-Weissman et al. stated that the number of infectious episodes within the first half year post LT is a major determinant of long-term survival (Leibovici-Weissman et al. 2021).

Study aims

The aim of this study is to investigate infections during the first posttransplant year in DBD and DCD liver recipients. Infection frequency is analysed in terms of number of infections over time and in the pathogen spectrum with regard to bacterial, fungal and viral infections. For this purpose, we kindly ask permission to access the STCS liver transplantation infections data from patients undergoing LT at the University Hospital of Zurich between 01/01/2016 and 30/09/2023. This encompasses a total of 418 individuals, with 143 being DCD recipients and 275 being DBD recipients.

Study design

In this retrospective, monocentric, observational study, we plan to analyse all adult deceased-donor orthotopic liver transplantation at the University hospital of Zurich between 01/01/2016 to 30/12/2023. Combined liver-kidney transplantations are excluded due to a different immunosuppressive regimen. Institutional collected demographic, surgery associated, and laboratory data are matched with the STCS data concerning postoperative infections in the first year after transplantation.

Lay summary

Descriptive title

After surgery infections (postoperative infections) in liver transplant recipients after Donation after Brain Death and Donation after Circulatory Death donation.

Main goals

To analyse the frequency and spectrum of microorganisms in DBD and DCD liver transplantation (LT) regarding postoperative infections in the first year after LT. Which treatment and samples are used: We will use laboratory and treatment associated data routinely obtained in perioperative phase, at the intensive care unit and during the follow up period. Those are partly collected in an intensive care unit database (KISIM) and partly in the STCS database. There is no specific treatment or intervention planned.

Why of interest

Postoperative infections are a main complication after transplantation and contribute to mortality and morbidity. Donation after Circulatory Death (DCD) was reintroduced in Switzerland in 2011 and accounts for a third of deceased organ donors today. Given the distinct procedures and guidelines for Donation after Brain Death (DBD) and DCD, coupled with the exposure of DCD organs to warm ischemia time, uncertainties persist regarding potential differences in infection outcomes. Therefore, we want to investigate if DCD is a risk factor for postoperative infections during the first year after LT.

Expected benefit

The findings have the potential to enhance the assessment for infections after liver transplantation, thereby offering valuable insights for treatment decisions such as initiating antibiotic or antifungal therapy.

FUP272

2026-04-28

Kidney transplants in patients under 20 years old at time of listing in Switzerland between 2008 and 2025 – a retrospective cohort study

Acceptance

Investigator

Franz Immer

Project summary

Background

In Switzerland, children and adolescents listed for kidney transplantation before the age of 20 receive priority within the national allocation algorithm, resulting in shorter expected waiting times for deceased donor transplantation compared with adults (1–4). In addition to transplantation from a deceased donor, living donor kidney transplantation represents an important alternative and is generally associated with shorter waiting times and favourable graft outcomes (5,6). However, due to prioritised access to high-quality deceased donor organs, the relative benefit of living versus deceased donor transplantation in this specific population remains unclear (7). To date, no systematic evaluation has assessed whether LD transplantation provides superior post-transplant outcomes compared with DD in candidates listed before the age of 20 in Switzerland since the introduction of the current allocation policy in 2008.

Study aims

The primary objective of this study is to compare kidney transplant outcomes of living vs. deceased donor organs in patients listed before the age of 20 years. Secondary objectives are: • To compare waiting list outcomes (transplantation, death, delisting, still waiting) • To assess post-transplant kidney function at defined time points • To compare graft survival and patient survival • To evaluate immunological risk factors, including HLA mismatch and sensitization • To assess early post-transplant outcomes such as delayed graft function

Study design

This retrospective observational cohort study will include all patients newly waitlisted for kidney transplantation in Switzerland between 1 January 2008 and 31 December 2025 who were younger than 20 years at the time of listing. Patients listed for multi-organ transplantation will be excluded. Data will be obtained from the STCS and the SOAS registries. Outcomes include waiting list events, transplantation by donor type, post-transplant kidney function, graft and patient survival, immunological parameters, and delayed graft function.

Lay summary

Descriptive title

Kidney transplantation outcomes in children and young people in Switzerland according to donor type

Main goals

Children and young people in Switzerland receive priority in the allocation of deceased donor kidney transplants. Alternatively to a deceased donor organ transplantation from a living donor is often also possible. This study will compare outcomes between living donor and deceased donor transplantation in patients listed before the age of 20.

Why of interest

In general, in adults living donation is associated with better results than deceased donor transplantation. However, in young patients the option of prioritization and optimum selection of deceased donor organs might lead to comparably good outcomes. It is therefore of high interest to study the results of transplantation in this specific situation.

Expected benefit

The results will help transplant teams and families to make informed decisions when choosing between living and deceased donor transplantation. The findings may also support future improvements in allocation policies and clinical care for young transplant candidates.

FUP271

2026-03-26

cPRA expansion and allocation fairness: Impact on Kidney Transplant Candidates, Allocation Times, Dialysis and Cold Ischemia Time in a 12-Month Pre- and Post-Analysis

Acceptance

Investigator

Agim Thaqi

Project summary

Background

The Swiss Organ Allocation System (SOAS) enables the organ allocation according to the Swiss federal law and considers donor, transplant, and recipient characteristics (donor and recipient age, height/weight, blood group, serology, donor-recipient immunological assessments, etc.). The HLA matching (Human Leukocyte Antigen) and the antibody constellation between the recipient and potential donors play a important role, as they significantly influence the success of a kidney transplantation. They help minimize the risk of a rejection and improve the long-term function of the transplanted organ. The introduction of the Luminex® technology made virtual crossmatching possible and allowed the calculation of cPRA for each transplant candidate. The cPRA estimates how many donors form the SOAS database would be compatible to a specific candidate. This quantitative assessment of anti-HLA antibodies also paved the way for considering organ offers even in the presence of donor-specific antibodies (DSA). The kidney allocation rules implemented in the current Swiss organ allocation system (SOAS) ensures that, independently of the immunization status all patient subgroups have a similar probability of receiving a kidney offer within an allocation process (even if this is sometimes difficult to achieve for highly immunized patients). A priority score is calculated for each kidney candidate on the waiting list who participates actively in an allocation process. The kidney priority score is the sum of three sub‐scores: the waiting time of patients with and without dialysis, the HLA matching score and the cPRA score. On April 1, 2024, Switzerland introduced adaptations in the HLA matching and calculation of the cPRA score in the kidney allocation rules.

Study aims

The goal of expanding cPRA to include HLA-C, -DQ, and -DP (in addition to HLA-A, -B, and -DR) is to provide a more accurate assessment of a transplant candidate’s immunologic sensitization, thereby improving risk prediction, ensuring fairer allocation priority for sensitized and highly sensitized patients. An adaptation in the HLA Matching score is done to better reflect current immunological evidence by incorporating clinically relevant loci such as HLA-DQ, thereby improving risk stratification and promoting donor–recipient combinations associated with better long-term graft outcomes, while maintaining fairness and balance within the allocation system. This change may lead i. to a reclassification of sensitization levels, ii. shift the priority and ranking during allocation, and iii. affect the time to transplant, dialysis, waiting time and the cold ischemia time (CIT) This could have a negative impact on the fairness principle of an immunization status (cPRA score) in an allocation The aim of this study is to investigate the effects of the adaptation to the kidney rules. If negative effects will be observed, the allocation rules must be refined to ensure fairness in kidney allocation. Patients included in this study were those listed on the transplant waiting list as of 01 April 2024. On that day, a total of 1,008 patients were listed. Until 31 March 2024, cPRA was calculated exclusively based on HLA-A, -B, and -DR antigens. On 01 April 2024, the cPRA calculation was expanded to HLA-Cw, -DP, and -DQ antigens. Changes in cPRA values before and after this methodological update were analyzed. Assessment of cPRA changes is clinically relevant because cPRA contributes to the allocation ranking score. Together with waiting time (with and without dialysis) and the HLA matching score (donor–recipient constellation), cPRA is a part of the allocation model used to support fair and equitable organ allocation. In a second step, kidney transplant recipients were analyzed for two distinct time periods: 01 April 2023 to 31 March 2024, representing the one-year period before implementation of the expanded cPRA calculation (and adaption of HLA Matching), and 01 April 2024 to 31 March 2025, representing the one-year period after the cPRA update.

Study design

This study is an observational, retrospective, comparative analysis of kidney allocation outcomes before and after the revision of allocation rules on April 1, 2024. The design allows assessment of the impact of changes in HLA matching criteria and cPRA calculation on allocation fairness, allocation efficiency, and short-termin clinical outcomes. - Pre-change period: April 1, 2023 – March 31, 2024 - Post-change period: April 1, 2024 – March 31, 2025

Lay summary

Main goals

This study aims to evaluate the effects of these rule changes. First, cPRA values before and after the methodological update are compared for patients who were on the transplant waiting list on April 1, 2024. Second, kidney transplant recipients are analyzed across two periods: • Pre-change: April 1, 2023 – March 31, 2024 • Post-change: April 1, 2024 – March 31, 2025 The study is a retrospective observational comparison designed to assess the impact of the changes on allocation fairness, allocation efficiency, and short-term clinical outcomes.

Why of interest

The Swiss Organ Allocation System (SOAS) allocates donor organs according to Swiss federal law and considers various donor and recipient characteristics. HLA matching and the recipient’s antibody profile are particularly important because they influence the risk of rejection and the long-term success of kidney transplantation. The introduction of Luminex® technology enabled virtual crossmatching and the calculation of the cPRA (calculated Panel Reactive Antibody), which estimates the proportion of compatible donors for a transplant candidate.

Expected benefit

On April 1, 2024, Switzerland updated the kidney allocation rules. The cPRA calculation was expanded to include HLA-C, -DQ, and -DP, in addition to HLA-A, -B, and -DR, and the HLA matching score was adjusted to better reflect current immunological evidence. These changes may affect sensitization classification, allocation priority, and factors such dialysis duration, waiting time, and cold ischemia time, potentially impacting the fairness of the allocation system.

FUP275

2026-06-03

Cellular EBV-specific Immunity in Kidney Transplant Recipients to Predict EBV Infections and PTLD

Acceptance

Investigator

Daniel Sidler

Project summary

Background

Kidney transplantation (KT) is often regarded as the best option for patients with advanced and dialysis-dependent renal disease 1. KT is associated with better quality of life, reduced morbidity, and increased patient survival when compared to long-term dialysis2. Patients can attain metabolic stability and eliminate end organ complications associated with long-term dialysis by regaining kidney function3. Despite these benefits, KT patients require lifelong immunosuppression to prevent graft rejection. Even though these medications promote transplant function, they increase a patient's susceptibility to infections, including opportunistic viral infections4. Among the most common illnesses among KT recipients are herpes viruses, particularly the Epstein-Barr virus (EBV). Serious clinical outcomes, including the potentially lethal illness known as post-transplant lymphoproliferative disease (PTLD), can result from these viruses 5. To optimize treatment strategies and minimize adverse outcomes, it is critical to understand the risks for EBV infections in connection with KT. EBV is a common herpes virus that - after a first infection - develops a lifelong latency in immunocompetent hosts. EBV-related problems in immunocompromised patients, including KT recipients may result from reactivation of the virus in patients with viral latency (intermediate risk patients) or from a primary infection in previously naive persons (high risk patients)5. Since saliva and other body fluids are the main way that EBV is spread, EBV-naïve KT patients may contract the virus from the donor organ. Indeed, EBV seronegative patients who receive an organ from a seropositive donor (D+/R-mismatch) are at highest risk for EBV-related problems5. The usual technique to ascertain a patient's past exposure to the virus is serological testing for EBV-specific IgG. A positive EBV IgG test reveals a history of infection and viral latency, yet also some degree of immunity. It is crucial to remember that humoral immunity has a limited function in controlling EBV viremia, hence EBV IgG by itself does not provide protection against viral reactivation and dissemination. Rather, viral suppression depends on cell-mediated immunity, especially T-cell responses6. The possibility of false-negative results, i.e. patients lacking IgG, yet mounting sufficient EBV T cell memory activity, is a major drawback of EBV IgG testing. This disparity emphasizes the necessity of extra diagnostic instruments to precisely determine a patient's actual immune state with respect to EBV. The ELISPOT (enzyme-linked immunosorbent spot) test has become a useful instrument for assessing T-cell responses to antigens, including microbial antigens, such as EBV7. ELISPOT directly evaluates the presence and function of pathogen-specific T cells, which are essential for viral control, in contrast to serological tests that measure antibodies 6,7. ELISPOT can give a more accurate picture of a patient's unique immunological competence by identifying the production of interferon-gamma (IFN-γ) from activated T cells in response to virus-specific antigens. ELISPOT assays unique to EBV have recently surfaced and are being used in clinical settings8. This test is especially helpful for determining which patients have protective cellular immunity even when they are EBV IgG-negative. Therefore, ELISPOT testing can improve risk stratification in KT recipient for later EBV primoinfection and EBV-related problems in the post-transplant follow-up. One of the major consequences of a negative EBV serology is that these patients do not qualify for immunosuppressive treatment with belatacept and other emerging immunosuppressive biologicals (iscalimab and others). According to the United States Food and Drug Administration (FDA), belatacept is indicated only for use in patients who are EBV seropositive, defined as having antibodies to EBV prior to initiation of therapy, due to the increased risk of PTLD in EBV-seronegative patients9. Belatacept has been shown to improve long-term renal function and reduce nephrotoxicity compared with standard calcineurin inhibitor (CNI)–based immunosuppression, while maintaining comparable patient and graft survival10–12. However, due to the higher incidence of PTLD, belatacept is contraindicated in EBV-seronegative patients. As it is estimated that approximately 5%–10% of individuals previously infected with EBV fail to develop antibodies to EBNA, a substantial proportion of patients may be incorrectly excluded from this therapy13. Another drawback is the incorrect risk stratification resulting from false-negative EBV serology in a high-risk population, which may expose these patients—besides causing potentially increased anxiety—to unnecessary tests and screening procedures.

Study aims

The purpose of this study is to assess the sensitivity, specificity, and utility of EBV ELISPOT from pre-transplant specimens of EBV IgG-negative transplant recipients predict EBV primoinfection. To do this, EBV-specific ELISPOT tests from bio banked baseline blood samples will be paired with prospectively collected clinical events, including EBV primoinfection, PTLD, graft loss, and death.

Study design

The study is designed as a nested study of the STCS cohort, specifically kidney transplant recipients and incorporates the analysis of baseline bio samples and clinical endpoints.

Lay summary

Main goals

This study will evaluate a newer laboratory test, called ELISPOT, which measures EBV-specific T-cell responses using blood collected before transplantation. By linking ELISPOT results to clinical outcomes after transplant - such as EBV infection and PTLD - we aim to determine whether this test can better predict who is truly at risk.

Why of interest

For people with advanced kidney failure, kidney transplantation is the best available treatment. Compared with staying on dialysis long term, transplantation helps people live longer, feel better, and avoid many serious complications. After a transplant, patients must take medications that suppress their immune system to avoid rejection of the transplanted organ. While these drugs are necessary, they also increase the risk of infections. One particularly important infection is caused by the Epstein–Barr virus (EBV), a very common virus that most people encounter during their lifetime. In transplant patients, EBV can sometimes lead to severe complications, including a rare but life-threatening cancer of the lymphatic system called post-transplant lymphoproliferative disorder (PTLD). Patients are regularly tested for EBV antibodies (EBV IgG) prior to transplantation to determine whether they had previously been exposed to the virus. This test does not, however, always provide the whole picture. While some people who test positive might still be at risk, others who test negative might still have immune cells that assist suppress EBV. Immune cells known as T cells, which are not detected by conventional antibody testing, are primarily responsible for protection against EBV.

Expected benefit

Ultimately, this research may improve how transplant patients are assessed before surgery and help doctors tailor care to reduce serious EBV-related complications and prevent situations in which patients with falsely negative EBV serologies are misclassified and consequently denied access to certain risk-adapted therapeutic options. One example of such treatment decisions concerns the immunosuppressive drug belatacept. This medication can help preserve kidney function better than some commonly used alternatives while providing similar protection against rejection. However, because patients without evidence of prior EBV infection have a higher risk of developing PTLD, current guidelines recommend its use only in patients who test positive for EBV antibodies before transplantation. Since a small but relevant proportion of people previously infected with EBV do not develop all antibodies typically measured in routine tests, some patients may appear EBV-negative despite prior infection. As a result, they may be unnecessarily excluded from treatments such as belatacept and may undergo additional monitoring or testing due to an incorrectly assumed higher risk.

FUP270

2026-04-30

BK Polyomavirus mRNA Vaccination Responses in Peripheral Blood Mononuclear Cells of Kidney Transplant Recipients

Acceptance

FUP269

2026-03-11

Fibrotic Hypersensitivity Pneumonitis: Clinical trajectories and genetic determinants of patient outcomes in the context of lung transplantation

Acceptance

Investigator

Pieter-Jan Gijs

Project summary

Background

Fibrotic hypersensitivity pneumonitis (fHP) is a progressive interstitial lung disease (ILD) that is increasingly recognized as an indication for lung transplantation (LTx). While recent guidelines have improved diagnostic criteria, fHP remains underrepresented in clinical studies. Emerging data indicate that a subset of fHP patients harbor telomere-related gene (TRG) variants or shortened telomeres. However, to date, no large-scale, dedicated study has evaluated fHP in the transplant setting, nor has telomere biology been systematically integrated into transplant risk stratification.

Study aims

This project aims: 1. to evaluate post-transplant outcomes in fHP patients compared to lung transplant recipients with other underlying diseases (e.g., other fibrotic ILDs, chronic obstructive pulmonary disease). 2. to investigate the role of telomer

Study design

The project is a retrospective, multicenter study including UZ Leuven, Centre universitaire romand de transplantation (CURT), which comprises the Centre Hospitalier Universitaire Vaudois (CHUV) and the Hôpitaux Universitaires de Genève (HUG), and Universitätsspital Zürich (USZ), with Swiss data extracted from the Swiss Transplant Cohort Study (STCS) and electronic health records of the patients. Clinical, radiologic, and histopathologic data will be collected, and telomere analyses will be performed on available blood and tissue samples. Genetic sequencing and telomere length assessment will be integrated to stratify patients and evaluate correlations with clinical outcomes.

Lay summary

Descriptive title

N/A

Main goals

Fibrotic hypersensitivity pneumonitis (fHP) is a serious lung disease caused by an abnormal reaction to inhaled environmental agents. Over time, it can lead to irreversible lung scarring and respiratory failure. For some patients, lung transplantation becomes the only life-saving option. However, fHP is still poorly studied in the transplant setting, and important differences between patients are not well understood. Recent research suggests that some fHP patients have abnormalities in their telomeres, which are structures that protect our chromosomes and are linked to aging and tissue repair. Short telomeres or genetic changes affecting telomere function may increase the risk of complications after lung transplantation. At present, this information is not routinely considered when transplant decisions are made.

Why of interest

The main goal of this study is to better understand how patients with fHP do after lung transplantation compared with patients transplanted for other lung diseases. A second key aim is to clarify whether telomere abnormalities influence survival, complications, and long-term outcomes after transplantation in fHP patients.

Expected benefit

The results of this study are expected to help doctors identify fHP patients at higher risk of complications earlier in the disease course. This may improve decisions about when to refer and list patients for lung transplantation and how to individualize their follow-up and treatment after surgery. In the long term, this work may contribute to safer and more personalized transplant care for patients with fibrotic lung diseases.

FUP268

2026-02-11

Pregnancy after Kidney Transplantation: Impact on Graft Function and Maternal-Fetal Outcomes in the Swiss Transplant Cohort Study

Acceptance

Investigator

Domenico Cozzo

Project summary

Background

Women affected by chronic kidney disease (CKD) experience a significant reduction in fertility, which progressively worsens as renal function declines (1). Pregnancy in women with CKD is associated with an increased risk of maternal complications, including acute kidney injury, worsening proteinuria, urinary tract infections, gestational hypertension, and preeclampsia, as well as adverse fetal outcomes such as preterm delivery, intrauterine growth restriction, higher rates of caesarean section, and postnatal complications (2). Kidney transplantation (KT) partially restores fertility, with approximately 2% of women of childbearing age with a functioning kidney graft achieving pregnancy (3, 4). Compared with women with advanced CKD, kidney transplant recipients generally exhibit higher birth rates and improved maternal outcomes (3, 4). Nevertheless, pregnancy after KT remains a high-risk condition, with potential implications for maternal health, graft function, and fetal outcomes. The majority of available evidence derives from single-center studies with limited sample sizes, while the highest level of evidence is largely based on narrative reviews. Overall, post-transplant pregnancies have been associated with increased maternal and neonatal risks, although graft function is typically affected only transiently (5, 11, 12).

Study aims

This study aims to determine the prevalence of pregnancy after kidney transplantation within the Swiss Transplant Cohort Study and to assess its impact on graft function. In addition, the study seeks to characterize the clinical course of pregnancy in kidney transplant recipients within a multicenter framework.

Study design

This is a multicentre, retrospective cohort study nested within the Swiss Transplant Cohort Study (STCS), including adult kidney transplant recipients followed between 2008 and 2025 who experienced at least one pregnancy after transplantation, compared with a reference cohort of women of childbearing age without post-transplant pregnancy. Follow-up will continue until death, graft failure, or the last recorded visit.

Lay summary

Descriptive title

N/A

Main goals

Chronic kidney disease can significantly reduce fertility in women and make pregnancy more difficult and riskier. Women with severe kidney disease who become pregnant have a higher chance of complications, such as high blood pressure, kidney problems, and early delivery, which can also affect the health of the baby. Kidney transplantation can partially restore fertility and allows some women to become pregnant. Compared with women who have advanced kidney disease, pregnancy outcomes are generally better after a successful transplant. However, pregnancy after kidney transplantation is still considered high risk and may affect the mother’s health, the transplanted kidney, and the baby. Despite this, most existing studies are small and come from single hospitals, meaning that important questions remain unanswered.

Why of interest

This study aims to better understand how often pregnancy occurs after kidney transplantation in Switzerland and how pregnancy affects the function of the transplanted kidney. Using data from a large national transplant cohort, we will study women who became pregnant after a kidney transplant and were followed over several years.

Expected benefit

By examining maternal health, kidney outcomes, and pregnancy-related complications, this research will provide valuable information to improve counseling, monitoring, and care for women considering pregnancy after kidney transplantation.

FUP267

2026-05-20

Epidemiology of catheter-related bloodstream infections (CRBSI) in solid organ transplant recipients and associated outcomes

Acceptance

Investigator

Peter Schreiber

Project summary

Background

Catheter-related bloodstream infections (CRBSI) are to the most common device-associated infections among healthcare-associated infections (HAI). In a Swiss point prevalence survey derived from the general hospital population CRBSI were found in 1.5% of all hospitalized patients [1]. CRBSI are relevant for patient outcomes, such as associated deaths, prolonged hospital stays and excess costs. Literature on HAI affecting solid organ transplant (SOT) recipients is limited in general. Data on CRBSI among SOT recipients seems very scarce. It can be hypothesized that the vulnerable population represented by SOT recipients might be at increased risk for inferior outcomes. The STCS represents an ideal platform for a comprehensive study of CRBSI in SOT recipients.

Study aims

The primary study aim is a description of the epidemiology and characteristics of CRBSI on SOT recipients. Secondary study aims are a) identification of variables associated with CRBSI caused by Gram-positive or Gram-negative pathogens and b) investigation of associations with adverse outcomes (death and/or graft loss within 1 year after CRBSI) and CRBS. We plan to use exclusively data already collected in the rich STCS dataset. SOT recipients with CRBSI will be identified in the STCS dataset by the combined infection site of “blood/bacteremia” and “catheter”. Information on recipient-specific data, transplant-specific data, CRBSI-specific data and outcome-specific data will be retrieved from the STCS database. We intend to describe the baseline characteristics of SOT recipients with CRBSI, the characteristics of CRBSIs and the observed adverse outcomes within 1 year after CRBSI. As outlined in the aims, we also intent a) to identify variables associated with CRBSI caused by Gram-positive or Gram-negative pathogens and b) to investigate associations with adverse outcomes and CRBSI.

Study design

Based on a preliminary analysis (query from August 2025), we identified 111 patients (21 CRBSI after heart transplantation, 55 CRBSI after kidney transplantation, 35 CRBSI after liver transplantation, 30 CRBSI after lung transplantation) with 141 events that were considered as CRBSI. Stratified by age at the time of transplant, we identified 100 adult SOT recipients with a CRBSI and 11 pediatric SOT recipients with a CRBSI. Due to the relatively small sample size, the main part of the project will be of descriptive nature, describing the epidemiology of affected SOT recipients, characteristics of CRBSIs and 1 year follow-up outcomes (death and/or graft loss). We also intend to perform a risk factor analysis for CRBSI caused by Gram-positive and Gram-negative pathogens. For this analysis, we intend to use logistic regression. Based on the number of causative pathogens, we will perform a multivariable analysis to identify independent associations with Gram-positive and Gram-negative pathogens, respectively. In addition, we intend to investigate associations with adverse outcomes and CRBSI. As outlined above, we intend to focus with this analysis on events occulting within 1 year after CRBSI. To address potential associations, we will use time to event models. If the number of events will be sufficient, multivariable analyses will be added and sensitivity analyses for the outcomes death and graft loss separately performed.

Lay summary

Descriptive title

Bloodstream infections related to the use of central venous catheters in solid organ transplant recipients

Main goals

We aim to improve our knowledge on this type of infection that is related to the use of central venous catheters, commonly abbreviated as CRBSI. Central venous catheters are frequently used, especially peri-transplant, as these catheters are often needed to administer specific drugs. These infections have been shown to be relevant for inferior patient outcomes such as death or longer hospital stay in the general patient population, but data specific for organ-transplant recipients are missing.

Why of interest

The main goal of the study is to describe the epidemiology of CRBSI and certain characteristics of these infections. We additionally aim to identify variables associated with certain pathogens and to address the relevance of CRBSI for inferior outcomes among solid organ transplant recipients.

Expected benefit

This study is relevant, as there is a lack of data on this infection in solid organ transplant recipients. A better understanding of the frequency, causative pathogens and relevance might help to improve patient care.

FUP266

2026-09-10

Seroprevalence of Transplant-Relevant Infectious Agents in Solid Organ Transplant Donors and Recipients Over Time

Acceptance

Investigator

Dionysios Neofytos

Project summary

Background

Solid organ transplantation saves lives but exposes recipients to a high risk of infections. Infectious diseases remain a major cause of illness and death after transplantation. These infections may be transmitted from the donor, result from reactivation of a latent infection in the recipient, or be newly acquired after transplantation under immunosuppression. Pre-transplant viral serostatus plays a key role in transplant care. It is essential for risk assessment, donor–recipient matching, and decisions on preventive and monitoring strategies. Viruses such as cytomegalovirus (CMV), Epstein–Barr virus (EBV), hepatitis viruses, HIV, and vaccine-preventable viruses directly affect patient outcomes and graft survival. Seroprevalence is not constant over time. It changes due to population ageing, migration, evolving vaccination coverage, and shifting indications for transplantation. In addition, seroprevalence differs by organ type because transplant populations vary in age, underlying disease, and prior exposures. In Switzerland, up-to-date nationwide data describing long-term trends in viral seroprevalence among both donors and recipients are limited. The Swiss Transplant Cohort Study (STCS), with its comprehensive and longitudinal national coverage, provides a unique opportunity to describe these trends and to better understand infectious risks in contemporary transplant practice.

Study aims

Primary aim To describe the pre-transplant seroprevalence of major transplant-relevant infectious agents among solid organ donors and recipients in Switzerland from 2008 to 2025. Secondary aims • To describe donor–recipient serostatus patterns for key infectious agents. • To compare seroprevalence across different organ transplant groups. • To examine demographic and clinical factors associated with viral serostatus. • To assess temporal and geographic changes in seroprevalence over the study period. • To explore the potential implications of serostatus profiles for post-transplant infectious risk stratification.

Study design

This is a multicenter, retrospective observational study conducted in Switzerland. It will include all pediatric and adult solid organ donors and recipients (heart, kidney, liver, lung, pancreas, pancreas-kidney, and small bowel) enrolled in the STCS between May 1, 2008, and December 31, 2025. Pre-transplant serological data for transplant-relevant infectious agents will be extracted from the STCS database, together with demographic and clinical information already routinely collected. The study will provide a nationwide overview of seroprevalence patterns and their evolution over time, as well as differences according to organ type and donor–recipient profiles.

Lay summary

Descriptive title

Infectious agents and Solid Organ Transplantation: What Has Changed Over Time?

Main goals

People who receive an organ transplant have a higher risk of infections. Some infections can come from the organ donor. Others may already be present in the patient before the transplant. Knowing this information is important to make transplantation safer. This project looks at how common important infectious agents are in organ donors and transplant patients in Switzerland. We study how this has changed over time. We also compare results by type of transplanted organ and by age.

Why of interest

This study is important because infection risks are not the same for everyone and change over the years. Better knowledge helps doctors understand today’s risks.

Expected benefit

The results can help improve transplant care. They may support better prevention, safer matching between donors and patients, and better protection of transplanted organs.

FUP265

2026-03-17

Aetiology, outcome and risk factors of respiratory tract infections in solid organ transplant recipients

Acceptance

Investigator

Jeanne Bisch-Karatas

Project summary

Background

Respiratory tract infections (RTIs), especially pneumonia, are common in solid organ transplant recipients [1-3] and contribute substantially to morbidity [4, 5] and mortality [6, 7]. In hospitalized solid organ transplant recipients (SOTr), bacterial pathogens account for most microbiologically confirmed pneumonias, although aetiology often remains unidentified and pathogen detection varies widely across studies [4-11]. Pathogen distribution and mode of acquisition change over time after transplantation, with nosocomial pneumonias being mostly due to Gram-negative bacilli, predominating in the early post-transplant period and community-acquired infections involving core respiratory pathogens (such as Streptococcus pneumoniae and Haemophilus influenzae) occurring later [4, 10]. Lung transplant recipients show higher rates of microbiologically confirmed bacterial RTIs, partly reflecting more intensive diagnostic strategies [7, 12]. Data on organ-specific pathogen-patterns, antimicrobial resistance, atypical bacterial pathogens, risk factors, long-term outcomes, and cardiovascular complications remain limited as existing evidence is largely derived from small, organ-specific [5, 8, 9, 11] or single-centre studies [7, 13, 14]. Comprehensive, nationwide cohort analyses of RTIs across all solid organ transplant recipients, stratified by transplant type, pathogens, and time since transplantation are lacking. This study aims to address these gaps by investigating the incidence, aetiology, including antimicrobial resistance, outcomes, and risk factors of bacterial RTIs across all types of SOTr, stratified by transplant type.

Study aims

The main objective of this study is to provide a comprehensive description of clinically significant respiratory tract infections (RTIs) in SOTr across all transplanted organ types. We aim to assess incidence, pathogen distribution including documented antimicrobial resistance, and outcomes including graft loss, mortality and cardiovascular events within 30-and 90- days after respiratory tract infection requiring hospitalization. In addition, we will evaluate the impact of different factors (age, sex, transplanted organ, date of transplantation, immunosuppressive regimen or induction therapy, TMP-SMX-prophylaxis at diagnosis, comorbidities) on the occurrence of these infections. Given the limited evidence on so-called atypical bacterial respiratory pathogens (Legionella spp., Mycoplasma pneumoniae, Chlamydia pneumoniae, Coxiella burnetii, and Francisella tularensis) in SOTr, we will provide a detailed descriptive analysis of this subgroup based on chart review and compare the incidence of legionellosis with the general Swiss population where feasible.

Study design

We aim to perform an analysis including all patients enrolled in the STCS since 2008 (approximately 7200 patients). As the events of interest in this project are RTIs requiring hospitalization, and hospitalization requirement was consistently recorded only from 2009 onwards, all analyses will be restricted to follow-up time from 2009 onwards, using left truncation (delayed entry) for participants transplanted before 2009. For analyses applying 90-day post-RTI risk windows, a washout period will be implemented at the beginning of the observation period (2009) to ensure complete exposure ascertainment. Variables of interest will be respiratory tract infections requiring hospitalization, causative pathogen, outcomes (death, graft-loss and cardiovascular events within 3 months), patient characteristics (age, sex, transplanted organ, date of transplantation, immunosuppressive regimen or induction therapy, TMP-SMX-prophylaxis at diagnosis, comorbidities). We will use descriptive statistics to illustrate baseline characteristics of patients. Additionally, we will use appropriate regression analysis to evaluate the impact of different factors (age, sex, transplanted organ, time since transplantation, immunosuppressive regiment, comorbidities) on the occurrence of these infections. Data for legionellosis of the general population will be obtained from the Federal Office of Public Health (FOPH), as done previously [15]. The data is available from the FOPH as all above-mentioned diseases have to be reported to the FOPH on a mandatory basis. Cumulative incidence of these infections will be calculated for the STCS-population and compared to incidences calculated for the general population (FOPH). Definitions of infection will follow the STCS Infectious Diseases guidelines.

Lay summary

Descriptive title

N/A

Main goals

Pneumonia is a significant threat to solid organ transplant recipients. The frequency is higher, and clinical courses are potentially more severe than in the general population, leading to hospitalization and death. Bacterial pathogens are responsible for most severe respiratory infections in transplant recipients; however, important aspects of their epidemiology, outcomes, and risk factors remain insufficiently understood.

Why of interest

Most existing studies focus on selected transplant groups, single organs, or the early post-transplant period, limiting our understanding of respiratory infections across different transplant types and over time. In particular, data comparing patterns of infection, causative pathogens, and outcomes between different transplanted organs are scarce. In addition, although current guidelines recommend empirical antibiotic treatment that includes coverage for so-called atypical bacterial pathogens, reliable data on their frequency, clinical relevance, and outcomes in transplant recipients remain limited.

Expected benefit

By systematically studying respiratory tract infections requiring hospitalization in solid organ transplant recipients, we aim to better define the incidence, clinical impact, and risk factors of these infections. Analyses stratified by transplanted organ, pathogen type, and time since transplantation will allow us to identify organ-specific patterns of disease. Where appropriate, comparisons with the general population will further contextualize our findings. Ultimately, this work aims to improve the evidence base for diagnosis, treatment, and prevention of clinically significant respiratory infections in this vulnerable population.

FUP264

2026-06-16

Who Benefits? Patient-Reported Quality of Life in Elderly Kidney Transplant Recipients: Insights from the Swiss Transplant Cohort

Acceptance

Investigator

Christian Kuhn

Project summary

Background

Kidney transplantation (KT) is the preferred therapy for kidney failure and generally improves survival and health-related quality of life (HRQoL; capturing disease-related physical and mental functioning rather than broader constructs such as overall quality of life or satisfaction), compared with dialysis. In recipients aged ≥65 years, the risk-benefit balance is less straightforward: early postoperative complications are more frequent, and any survival advantage may be attenuated or delayed. For many older adults, HRQoL is as important as or more important than, longevity when weighing treatment options. HRQoL after KT has been relatively underrepresented compared with survival and graft outcomes in older recipients. Existing investigations often enroll small cohorts, include older adults as subgroups rather than as a primary population of interest, and tend to rely on global HRQoL measures without exploring domain-specific changes or the influence of early post-transplant complications. Few studies have applied standardized, validated HRQoL instruments in a longitudinal framework that explicitly links early clinical events to subsequent patient-reported outcomes. In line with the Standardized Outcomes in Nephrology-Kidney Transplant (SONG-Tx) Initiative, outcomes that reflect day-to-day life participation deserve greater emphasis. This study examines overall and domain-specific HRQoL at 12 months in kidney transplant recipients aged ≥65 years, using standardized, validated measures (EQ-5D-5L utility index and domains, and EQ-VAS), and evaluates the impact of early severe adverse events. HRQoL will be analyzed in relation to baseline clinical and sociodemographic characteristics and to early post-transplant complications occurring within the first six months (infections, cardiovascular events, malignancies, and allograft rejection).

Study aims

Our goal is to generate evidence that supports individualized, patient-centered decisions for older transplant candidates and to lay groundwork for targeted interventions (e.g., prehabilitation or tailored aftercare) aimed at improving participation and overall quality of life. Overall aims: • To describe the evolution of HRQoL in kidney transplant recipients aged ≥65 from pretransplant (baseline) to 12 months posttransplant • To evaluate the impact of early post-transplant complications (i.e. infection, cardiovascular event, malignancy, treated rejection) on HRQoL at 12 months posttransplant. Primary objective: • Assess the association between any early (0–6 months) severe adverse event (SAE; infection, cardiovascular event, malignancy, treated rejection) and 12-month HRQoL. Secondary objectives 1. Descriptive Objectives • Describe HRQoL trajectories from baseline (pre-KT) to 6 and 12 months after KT. • Characterize the type and burden (number) of SAEs occurring within the first 6 months post-transplant. • Summarize 12-month HRQoL across EQ-5D-5L domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). • Describe life participation-related outcomes at 12 months (usual activities). 2. Inferential Objectives • Identify baseline clinical and sociodemographic predictors of 12-month HRQoL. • Examine the associations between SAE type and burden (number of SAEs) and overall and domain-specific HRQoL outcomes (i.e. mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and life participation (usual activities/physical activity proxies). • Estimate the proportion who improve or maintain high HRQoL at 12 months, and assess predictors and SAE-related differences (responder analysis).

Study design

This subanalysis of the STCS, a prospective open cohort study, will include kidney transplant recipients aged ≥65 years from the STCS who completed at least one of the EQ-5D questionnaires at baseline (pre-transplant), 6 months, or 12 months post-transplant. The primary outcome is HRQoL at 12 months, assessed across five EQ-5D domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-VAS will be analyzed as a secondary measure of overall health perception.

Lay summary

Descriptive title

N/A

Main goals

A kidney transplant is often considered the best treatment for people with kidney failure. It can help people live longer and feel better than dialysis. However, as more older patients receive kidney transplants, it’s not always clear whether they benefit equally, especially when complications or other health problems occur. This study focuses on older (aged 65 and above) kidney transplant recipients in Switzerland. We want to understand how quality of life changes during the first year after the transplant, and what factors might influence this, such as age, physical fitness, or early complications like infections or rejection. We will use questionnaires completed by patients before the transplant and again at 6 and 12 months. These questionnaires ask about daily activities, mobility, pain, and mental well-being. We will also use other information collected by the STCS, including early complications in the first 6 months after transplant, to understand patterns and trends.

Why of interest

We aim to find out: • Who feels better after the transplant — and who doesn’t? • How do early serious complications affect downstream everyday life? • Can we better predict which patients will benefit the most in terms of quality of life?

Expected benefit

Our goal is to give patients and doctors clear, practical information to support personalized decisions—not only about living longer, but also about improving everyday quality of life in ways that matter to patients.

FUP263

2026-01-16

High-sensitivity C-reactive protein (hs-CRP) and prediction of cardiovascular risk in the Swiss Transplant Cohort Study

Acceptance

Investigator

Krishna Sheth

Project summary

Background

Cardiovascular diseases (CVD) are the leading cause of mortality worldwide and can be predicted by cardiovascular (CV) risk factors with equations such as the Framingham risk score. CVD affect solid organ transplant (SOT) recipients with a higher incidence as compared to the general population, but the medical management and prediction of CVD events is less clear for SOT recipients. A few predicting tools have been developed, but not yet validated. Moreover, they relate to specific organ recipients, such as kidney or liver transplant recipients. Lipoprotein(a) and high-sensitivity C-reactive protein (hs-CRP) are promising biomarkers to stratify the cardiovascular risk in the general population but data are lacking in transplantation medicine.

Study aims

In this nested study within the Swiss Transplant Cohort Study (STCS), we aim to assess the association of CVD outcomes with classic CV risk factors and organ-specific and non-organ- specific factors in SOT recipients. This project proposal is an extension to FUP138 and FUP258, projects already approved by the STCS. Aim 1. To evaluate hs-CRP levels as a novel biomarker of cardiovascular risk (and possible target of pharmacological treatment) in solid-organ transplant recipients.

Study design

To develop accurate prediction models, this project will gather data from all STCS centers on each SOT recipient in the database from inception, who had a single organ transplant for the first time and with a minimum follow-up of 1 year, i.e. from May 2008 to December 2026. A part of requested data is already available in the current STCS database and additional analysis of hs-CRP levels in plasma samples of SOT recipients is planned. We will first conduct descriptive analyses of baseline characteristics, overall and stratified by the type of SOT, as we expect differences between SOT groups. We will then run prediction models using logistic and Cox proportional hazard regression analyses as appropriate, to assess which cofactors are predictive of CVD outcomes. The prediction models will focus on CVD outcomes, i.e. coronary revascularization, myocardial infarction, stroke, peripheral artery disease, death and cause of death. Independent variables of the prediction models will include the classic CV risk factors (demographics, lifestyle, vital signs, full lipid profile, glucose, HbA1c, creatinine), pre- transplant diagnoses (diabetes, hypertension, dyslipidemia, chronic kidney disease [CKD], prior CVD) and pre-transplantation medication. The factors related to grafts will include the primary disease, SOT type, time since transplantation, immunosuppressive treatment regimen and adherence, as well as graft-related complications, medical complications (e.g. neoplasia) and infectious disease factors.

Lay summary

For transplant patients

- Descriptive, plausible title: Post-transplant high-sensitivity C-reactive protein (hs-CRP) levels and their capacity of predicting cardiovascular risk in solid-organ transplant patients of the Swiss Transplant Cohort Study - Main goals/questions of the study: The goal is to develop better tools to identify transplant recipients at high risk of heart disease and complications. This could help doctors personalize treatments, improve long-term health, and protect the transplanted organ. Researchers will use information from over 7,000 transplant recipients in the Swiss Transplant Cohort Study to look at traditional risk factors (like high blood pressure or diabetes). They will also study a blood marker — high-sensitivity C-reactive Protein (hs-CRP) —that may help predict future heart problems. - Short, relevant information about why the study is of interest: People who receive a heart, kidney, liver, or lung transplant live longer thanks to improved medical care. However, they are more likely to develop heart and blood vessel diseases (cardiovascular disease, or CVD) after transplantation. This project seeks to understand why that happens and how to predict it earlier. - What benefit or significance is expected from the results for patients and professionals?: If hs-CRP is proven to have significant predictive value in cardiovascular risk assessment, the expected benefit is improved post-transplant monitoring and more tailored patient care.

Descriptive title

Post-transplant high-sensitivity C-reactive protein (hs-CRP) levels and their capacity of predicting cardiovascular risk in solid-organ transplant patients of the Swiss Transplant Cohort Study

Main goals

The goal is to develop better tools to identify transplant recipients at high risk of heart disease and complications. This could help doctors personalize treatments, improve long-term health, and protect the transplanted organ. Researchers will use information from over 7,000 transplant recipients in the Swiss Transplant Cohort Study to look at traditional risk factors (like high blood pressure or diabetes). They will also study a blood marker — high-sensitivity C-reactive Protein (hs-CRP) —that may help predict future heart problems.

Why of interest

People who receive a heart, kidney, liver, or lung transplant live longer thanks to improved medical care. However, they are more likely to develop heart and blood vessel diseases (cardiovascular disease, or CVD) after transplantation. This project seeks to understand why that happens and how to predict it earlier.

Expected benefit

If hs-CRP is proven to have significant predictive value in cardiovascular risk assessment, the expected benefit is improved post-transplant monitoring and more tailored patient care.

FUP262

2026-02-04

Preventable Causes of Death among Solid Organ Transplant Recipients in Switzerland

Acceptance

Investigator

Laura Naëmi Walti

Project summary

Background

Despite substantial recent progress, solid organ transplantation (SOT) is still associated with elevated mortality: In a recent study, SOT recipients in the US had a 4-fold risk of death when compared to the general population (1). Survival and causes of death vary by the type of organ transplant (2). However, over the last three decades the leading causes of death in the SOT population changed from graft failure to cancer and heart disease (1). A thorough understanding of potentially preventable causes of death, including vaccine-preventable infections, screenable cancers, and preventable metabolic disorders, can help identify unmet needs in prevention and guide future public health strategies. Understanding the causes of death among our SOT recipients is crucial for improving long-term outcome following SOT. The STCS with its systematic data collection on infections, cancers, metabolic diseases and causes of death, provides an ideal foundation for this analysis. Additionally, the Swiss Federal Statistical Office compiles detailed cause-of-death data for the general population, categorized by year, sex, and age (3).

Study aims

The study aims to compare age-adjusted mortality rates of SOT recipients and of the general population for specific causes of death with a focus on mortality rates for potentially preventable causes (vaccine preventable infections, screenable cancers, cardiovascular death) in Switzerland (primary objective). Additionally, we will report the causes of death stratified by the type of organ transplant, sex, and the decade of transplantation and the time after transplant (within the first year post-transplant and beyond).

Study design

We plan to perform an analysis including all patients enrolled in the STCS since 2008 (approximately 7800 patients). Variables of interest will include patient characteristics (such as transplanted organ, date of transplantation, underlying disease) and cause of death as recorded by the STCS. The incidence of respective causes of death in the SOT population will be compared with the general population. Data for causes of death in the general population will be obtained from the Federal Office of Statistics (FOS). Descriptive statistics will be used to illustrate baseline characteristics of patients. Using the STCS data (for SOT patients) and FOS data for the general population, we will calculate standardized mortality ratios (SMRs), as previously described (1), to compare the risk of death from preventable causes between the two groups . Preventable causes of death will be defined as death due to screenable cancers, vaccine preventable infections, and cardiovascular death.

Lay summary

For transplant patients

Solid organ transplantation is associated with an increased risk of death compared to the general population. To understand why SOT recipients die is of utmost importance. Moreover, we aim to understand if some of the causes of death are potentially preventable, including vaccine-preventable infections, screenable cancers, and preventable metabolic disorders. To do this we will compare causes of death in SOT recipients with the general population. This will help us gain a better understanding of unmet needs in prevention and guide future public health strategies, potentially improving long-term outcomes following transplantation.

FUP261

2025-09-22

Health-related quality of life (QoL) in older kidney transplant recipients A meta-analysis of Swiss, Norwegian and Dutch KT recipients.

Acceptance

FUP260

2026-12-09

Leucopenia in Kidney Transplant Recipients: Uncovering Prevalence, Risks, and Clinical Outcomes – A Deep Dive into STCS

Acceptance

Investigator

Federica Bocchi

Project summary

Background

Kidney transplantation (KT) is the preferred treatment for patients with advanced kidney failure, offering significant advantages over long-term dialysis in terms of survival, comorbidity management, and quality of life (1-2). However, lifelong immunosuppressive therapy, essential to prevent rejection, is associated with a range of complications, including bone marrow suppression, blood cell abnormalities and infection. Blood cytopenias - such as anemia, leukopenia, thrombocytopenia, or pancytopenia - are frequently observed after KT, especially within the first six months (3-5). It may result from bone marrow suppression secondary to immunosuppressive drugs (e.g., mycophenolate mofetil, ATG), antiviral prophylaxis (e.g., valganciclovir), or concomitant infections (6-8). Clinically, leukopenia is particularly concerning because it predisposes patients to severe or opportunistic infections, which are major contributors to post-transplant morbidity, hospitalizations, and graft loss. The duration of leukopenia may further modulate risk, with prolonged episodes likely conferring greater susceptibility than isolated transient events (9). Despite its clinical relevance, the prevalence, determinants, and impact of early post-transplant leukopenia on infectious complications remain incompletely characterized. Existing studies are limited by small sample sizes, heterogeneous definitions of leukopenia, and inconsistent follow-up, highlighting the need for a large, multicenter investigation. This study aims to fill this gap by evaluating the association between leukopenia during the first six months after KT and the subsequent risk of severe or opportunistic infections, as well as related clinical outcomes, in a well-characterized national cohort.

Study aims

This study aims to evaluate the association between leukopenia within the first 6 months after KT and the occurrence of relevant and/or opportunistic infections within the first post-KT year.

Study design

This is a multicentre, retrospective cohort study nested within the Swiss Transplant Cohort Study (STCS), including all adult KT recipients between 2008 and 2024. Patients will be followed until death, graft loss, or censoring at last follow-up.

Lay summary

For transplant patients

English version Low White Blood Cells After Kidney Transplant: What’s the Risk of Serious Infections? Kidney transplantation is the best treatment for people with advanced kidney failure, improving survival, quality of life, and overall health compared with long-term dialysis. However, patients need lifelong medications to prevent rejection, which can affect the bone marrow and reduce blood cell counts, sometimes leading to infections. One important complication is leukopenia, a low number of white blood cells, which can increase the risk of serious or unusual infections. The risk may be higher if the low white blood cell counts last longer rather than being short and temporary. Currently, we do not fully understand how often leukopenia occurs after kidney transplantation, what factors cause it, and how it affects infections and other complications. This study will investigate these questions in a large national group of kidney transplant recipients, focusing on leukopenia during the first six months after transplant and its link with severe or opportunistic infections, hospitalizations, and graft health. French version Leucopénie après une greffe rénale : quel risque pour les infections graves? La transplantation rénale est le traitement de choix pour les personnes atteintes d’insuffisance rénale avancée, offrant une meilleure survie, une meilleure qualité de vie et une santé globale supérieure à celle de la dialyse à long terme. Cependant, les patients doivent prendre des médicaments à vie pour prévenir le rejet du greffon, ce qui peut affecter la moelle osseuse et réduire le nombre de cellules sanguines, augmentant parfois le risque d’infections. Une complication importante est la leucopénie, une diminution des globules blancs, qui accroît le risque d’infections graves ou opportunistes. Le risque semble plus élevé lorsque la leucopénie dure longtemps plutôt que lorsqu’elle est courte et transitoire. Actuellement, on ne comprend pas complètement la fréquence de la leucopénie après la greffe rénale, ses causes et son impact sur les infections et d’autres complications. Cette étude vise à répondre à ces questions dans un large groupe national de patients transplantés, en se concentrant sur la leucopénie pendant les six premiers mois après la greffe et son association avec les infections graves, les hospitalisations et la survie du greffon. German version Leukopenie nach Nierentransplantation: Welches Risiko für schwere Infektionen? Die Nierentransplantation ist die bevorzugte Behandlung für Menschen mit fortgeschrittener Niereninsuffizienz und verbessert Überleben, Lebensqualität und allgemeine Gesundheit im Vergleich zur langfristigen Dialyse. Allerdings müssen Patienten lebenslang Medikamente einnehmen, um eine Abstoßung zu verhindern, die das Knochenmark beeinflussen und die Anzahl der Blutzellen reduzieren können, was das Infektionsrisiko erhöhen kann. Eine wichtige Komplikation ist die Leukopenie, ein niedriger Wert weißer Blutkörperchen, der das Risiko für schwere oder opportunistische Infektionen erhöht. Das Risiko scheint höher zu sein, wenn die Leukopenie länger anhält, anstatt nur kurzzeitig aufzutreten. Derzeit ist nicht genau bekannt, wie häufig Leukopenie nach einer Nierentransplantation auftritt, welche Faktoren sie verursachen und wie sie Infektionen und andere Komplikationen beeinflusst. Diese Studie untersucht diese Fragen in einer großen nationalen Kohorte von Nierentransplantierten, mit Fokus auf Leukopenie in den ersten sechs Monaten nach der Transplantation und deren Zusammenhang mit schweren oder opportunistischen Infektionen, Krankenhausaufenthalten und das Überleben des Transplantats.

FUP259

2025-09-22

MiSMATCh study – a collaboration to better understand the harms associated with acquiring CMV at kidney or liver transplant

Acceptance

FUP258

2025-06-11

Prediction of cardiovascular risk in the Swiss Transplant Cohort Study

Acceptance

FUP257

2025-06-11

Mechanisms and signatures of immune tolerance following combined kidney and hematopoietic stem cell transplantation

Acceptance

FUP256

2025-06-11

Prevalence of genetic causes in SARD-ILD requiring lung transplantation (Project name: Socrate)

Acceptance

FUP255

2025-06-25

Prognostic Impact of Cardiovascular- Kidney-Metabolic Burden Among Heart Transplant Patients

Acceptance

FUP254

2025-06-11

Incidence of HPV-related cancers in solid organ transplant recipients: a retrospective cohort study in Geneva

Acceptance

FUP253

2025-06-17

The impact of recipient age on the incidence of rejection and infection after kidney transplantation

Acceptance

FUP251

2025-08-06

Vaccine Immunity in Pediatric Solid Organ Transplant Recipients

Acceptance

FUP250

2025-03-17

AIIDKIT: Artificial Intelligence for Improved Infectious Diseases Outcomes in Kidney Transplant Recipients

Acceptance

FUP249

2025-03-17

Epidemiology of glomerulonephritis in Swiss kidney transplant recipients

Acceptance

FUP248

2025-07-22

Unravelling the interplay between solid organ transplantation and de novo or deteriorating chronic kidney disease: risks, predictors, and outcomes – a Swiss Transplant Cohort Study

Acceptance

FUP247

2025-08-18

Belatacept in kidney transplantation: the Swiss experience

Acceptance

FUP246

2026-07-20

Optimizing Vaccination Strategies Against Respiratory Viruses in Solid Organ Transplant Recipients

Acceptance

FUP245

2025-08-21

Immunogenicity of RSV vaccines in solid organ transplant recipients – a randomized comparative pilot trial

Acceptance

FUP244

2025-07-23

Belatacept use and associated outcomes in adolescent Swiss Kidney Transplant Recipients

Acceptance

FUP243

2025-03-13

Impact of induction therapy on patient and allograft outcomes in liver transplant recipients with preformed donor-specific antibodies

Acceptance

FUP242

2025-11-13

Quality of life and psychological symptoms among patients undergoing pancreas and islet transplantation in Switzerland: A retrospective multi-centre comparison study

Acceptance

FUP241

2024-12-12

International Organ Utilisation Collaborative (IOUC) data collection and analysis

Acceptance

FUP240

2025-03-03

Comparative long-term outcomes of pancreas versus islet of Langerhans transplantation: a nationwide cohort study

Acceptance

FUP239

2024-10-04

Sex/gender-dependent differences in the epidemiology and outcome of kidney transplantation in Switzerland

Acceptance

FUP238

2024-12-12

Morbidity and mortality of atypical bacterial pneumonia in solid organ transplant recipients

Acceptance

FUP237

2024-09-23

Antimicrobial resistance in solid organ transplant recipients and the general population – a nation-wide study combining STCS and ANRESIS data

Acceptance

FUP236

2024-09-23

Analysis of Rare Complications in Kidney Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease: Insights from the STCS

Acceptance

FUP235

2024-09-03

Systematic review of Donor-derived-infections after a solid organ transplantation between 2012 and 2023

Acceptance

FUP234

2024-10-18

Morbidity and mortality of respiratory viral infections in solid organ transplant recipients – impact of COVID-19

Acceptance

FUP233

2024-06-19

Postoperative infections in liver transplant recipients after DBD and DCD donation

Acceptance

FUP232

2024-07-16

Epidemiology and outcomes of acyclovir/foscarnet-refractory/resistant mucocutaneous HSV infections in allogeneic hematopoietic cell transplant recipients

Acceptance

FUP231

2024-03-21

Host Genetic Risk Factors for Infectious Diseases in Solid Organ Transplant Recipients

Acceptance

FUP230

2024-02-06

Phenotypes of post-liver transplant graft failure revealed by unsupervised machine learning clustering

Acceptance

FUP229

2024-03-13

Incidence and Outcome of Thrombotic Microangiopathy in Organ Transplant Recipients: A Comparative Study

Acceptance

FUP228

2024-03-13

Long-term Azithromycin exposure and posttransplant cancer risk in lung transplant recipients

Acceptance

FUP227

2025-03-10

Quality of life and mental health in Swiss pediatric solid organ transplant recipients

Acceptance

FUP226

2024-09-12

AIIDKIT: Artificial Intelligence for Improved Infectious Diseases Outcomes in Kidney Transplant Recipients

Acceptance

FUP225

2025-01-06

Machine perfusion in diseased donor kidney transplantation

Acceptance

FUP224

2024-06-24

Rare fungal infections in solid organ transplantation recipients

Acceptance

FUP223

2024-01-04

Evaluation of the implementation of a CMV cell-mediated immune assay in the routine clinical practice for the prevention of CMV infection in CMV-seropositive kidney transplant recipients

Acceptance

FUP222

2024-02-06

Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study (2008-2022)

Acceptance

FUP221

2023-12-07

Personalized Post-Transplant Risk Prediction with Explainable Machine Learning

Acceptance

FUP220

2023-09-06

Sex disparities in infections after solid organ transplantation – An analysis by the Swiss Transplant Cohort Study

Acceptance

FUP219

2023-09-15

The diagnostic performance of an EBV DNAemia to predict PTLD among solid organ transplant recipients using machine learning algorithms

Acceptance

FUP218

2023-10-02

Non-microbiologically confirmed infections in solid organ transplant recipients

Acceptance

FUP217

2023-07-07

Predictors for short- and long-term complications in ABO-incompatible kidney transplantation

Completed

FUP216

2023-06-27

Predicting longevity of kidney transplant patients up to and at 25 years in the Swiss Transplant Cohort Study (STCS)

Acceptance

FUP215

2023-06-19

Brain abscesses in transplant recipients: a multicentre retrospective study

Acceptance

FUP214

2023-09-19

Comparison of variable selection strategies in transplant data

Acceptance

FUP213

2023-07-25

Outcome of dual kidney transplantation in Switzerland - a national cohort study

Acceptance

FUP211

2023-07-17

Identification of biomarkers for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Acceptance

FUP210

2023-06-13

Differences between the Observed and Expected Serum Creatinine Range after Kidney Transplantation

Acceptance

FUP209

2023-05-31

Immunosuppression minimisation after liver transplantation: a multicentre, prospective, randomised and controlled clinical trial

Acceptance

FUP208

2024-11-18

The role of normothermic regional perfusion by means of veno-arterial extracorporal membrane oxygenation in DCD renal allograft outcomes

Acceptance

FUP207

2023-12-07

10 years of kidney paired exchange in Switzerland: a comparison with deceased and direct donor's kidney transplantation

Acceptance

FUP205

2022-11-18

Epidemiology of invasive Candida infections in solid organ transplant recipients over time and risk factor analysis based on the Swiss Transplant Cohort Study

Completed

FUP204

2022-11-17

Burden of infection in solid organ transplant recipients during long term follow-up

Acceptance

FUP203

2022-11-23

Prevalence, evolution, determinants, and outcomes of self-reported physical activity among solid organ transplant groups: Analysis of the prospective Swiss Transplant Cohort Study [PROSPECTFIT]

Acceptance

FUP202

2022-10-28

Invasive aspergillosis in liver transplant recipients in the current era

Completed

FUP201

2022-06-02

Epidemiology and outcomes of infectious complications in heart transplant recipients at the Lausanne University Hospital (CHUV)

Acceptance

FUP200

2022-06-03

Decay of vaccine-specific antibodies among solid organ transplant patients

Acceptance

FUP199

2022-04-12

Predictive and prognostic factors for short and long-term complications after kidney transplantation

Acceptance

FUP198

2022-03-30

Does kidney transplantation improve survival in the current era in Europe?

Acceptance

FUP197

2022-04-27

Valganciclovir dosing as primary CMV-prophylaxis in association with renal function in kidney transplant recipients

Acceptance

FUP196

2024-02-19

Liver transplantation for hepatitis D virus in Switzerland: a retrospective cohort study

Acceptance

FUP195

2022-05-25

Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus spp. (VRE) colonization and infection in Swiss solid organ transplant recipients and risk factor analysis

Acceptance

FUP194

2022-07-01

Evolution of Health-Related Behaviors and their Correlation with Outcome Parameters in Allogeneic Stem Cell Transplantation: A Secondary Data Analysis of the Swiss Transplant Cohort Study

Acceptance

FUP193

2022-09-23

Evolution of Emotional Burden and its Impact on Mortality in Stem Cell Transplanted Patients: A Prospective, Longitudinal Study of the Swiss Transplant Cohort Study

Acceptance

FUP192

2022-05-30

Clinical prediction model for the prognosis in kidney-transplanted patients

Completed

FUP191

2022-04-12

Development of a risk score model for Aspergillus infection in lung transplant recipients - an international multicenter study

Acceptance

FUP190

2023-02-22

Effects of interpersonal trust in the transplant team on health and behavioural outcomes over time: A secondary analysis of the Swiss transplant cohort study

Acceptance

FUP189

2022-01-26

A Survey on COVID-19 Vaccine Hesitancy in Solid Organ Transplant Recipients

Acceptance

FUP188

2021-12-14

Überleben und Lebensqualität nach Lebertransplantationen bei alkoholbedingten Lebererkrankungen mit und ohne präoperativer Alkoholabstinenz

Completed

FUP187

2021-12-09

Adjunctive glucocotricod therapy in solid organ transplant recipients with Pneumocystis Jirovecii Pneumonia (PJP)

Completed

FUP186

2022-03-08

Infectious Diseases in the First Year After Solid Organ Transplantation in children in the Swiss Transplant Cohort Study

Acceptance

FUP185

2022-03-14

Differences in infectious disease event after kidney transplantation in people living with HIV and kidney re transplantation in HIV-uninfected patients

Completed

FUP184

2021-12-09

Crescent prevalence in native kidney biopsy of IgA nephropathy patients that underwent kidney transplant at CHUV over the past 20 years: a real-world single-center retrospective cohort analysis

Acceptance

FUP182

2021-09-01

Description of the evolution and center variability of post-transplant non-adherence to immunosuppressants in kidney transplantation: A secondary analysis of the Swiss Transplant Cohort Study

Completed

FUP181

Outcomes of liver transplant recipients with autoimmune hepatitis as initial indication in the STCS

Acceptance

Investigator

None

Project summary

Background

Autoimmune hepatitis (AIH) is a progressive inflammatory liver disease, characterized by elevated liver function tests and immunoglobulin levels, interface hepatitis and by the presence of specific autoantibodies, that mainly affects females (1). Since the introduction of immunosuppressive treatment, the 10-year survival has drastically changed, increasing from 10% to >90%; nevertheless, if left untreated, AIH can progress to liver failure and require liver transplantation (LT) (2). LT in the context of AIH has a relatively good prognosis with a 10-year survival superior to 75%. However, a recent long-term analysis suggested a higher mortality at 1 year post-LT for AIH compared to other liver diseases (3). Moreover, two recent European and American studies showed that LT patients with AIH were at increased risk for death and graft loss from infections compared with other indications, in particular lethal fungal infections (4,5). Recurrent AIH after LT (rAIH), which can cause allograft dysfunction and result in the need for re-transplantation, has been reported in 17% to 42% of the transplant recipients. rAIH has been associated with increased serum aminotransferase and IgG levels after LT, as well as the presence of moderate to severe inflammation in the explant. Other risk factors, such as donor-recipient HLA mismatching, previous episodes of rejection, discontinuation of corticosteroid therapy and inadequate immunosuppression, have been described but never firmly established (6). Finally, a substantial part of the patients with AIH are women of child-bearing age. Pregnancies after LT are possible in stable long-term LT recipients. The outcome is good but an increased risk of pre-term delivery, low birth weight, hypertension, and preeclampsia has been described (7).

Study aims

Our aims are the following: Aim 1. To describe the outcomes (patient and graft survival, re-transplantation, acute and chronic rejection, biliary and vascular post-transplant complications, post-transplant infections) of patients transplanted for AIH in the STCS Aim 2. To compare the outcomes (same as above) of patients transplanted for AIH with outcomes of patients transplanted for alcohol-related liver disease, viral-related liver disease and other autoimmune liver diseases (namely primary biliary cholangitis and primary sclerosing cholangitis). Aim 3. To assess the prevalence of rAIH in the STCS and determine if some risk factors (pre-LT immunosuppressive treatment history, post-LT immunosuppressive treatment regimen, donor/recipient human leukocyte antigen mismatch, living vs. deceased-donor LT) for rAIH can be identified Aim 4. To collect data on pregnancies after LT for AIH in the STCS and describe the fetal and maternal outcomes (in particular pre-term birth, low-birth weight, preeclampsia, gestational diabetes, etc.) in patients transplanted for AIH in comparison with patients transplanted for alcohol-related liver disease, viral-related liver disease and primary biliary cholangitis

Study design

All LT recipients participating in the STCS from May 2008 to May 2021 will be included in our study. We aim to focus on and comprehensively describe the AIH LT population and compare the outcomes of this population to control groups (namely patients transplanted for alcohol-related disease, viral disease and other autoimmune diseases). We also plan to run another comparative analysis after having matched AIH LT recipients and control groups for age, sex and race. The requested data for Aims 1 and 2 is recorded in the STCS database and the complete set of requested variables is detailed in this document (Paragraph 2.3.3.). For Aim 3, we expect some inconsistencies in the STCS database and a chart review with, in particular, a careful and systematic review of post-LT liver biopsies may be necessary for the AIH LT recipients. Finally, for Aim 4, we expect to have incomplete data for maternal outcomes, whereas the fetal outcomes are not collected in the STCS database. As this will regard only a limited number of patients, we will collect the information case by case with the help of a Case Report Form. Besides, an intercohort collaboration between the STCS and the Swiss Autoimmune Hepatitis Cohort Study is underway, the Letter of Intent having been approved by the Scientific Committee of the latter. Of note, information on pregnancies is collected in the Swiss Autoimmune Hepatitis Cohort Study.

Lay summary

For transplant patients

Autoimmune hepatitis is a rare inflammatory disease of the liver that can cause severe liver disease and lead to liver transplantation if left untreated. We will take advantage of the Swiss Transplant Cohort Study and the Swiss Autoimmune Hepatitis Cohort Study to collect recent data on the outcomes of patients transplanted for this indication in Switzerland and compare these with patients transplanted for other indications. We will try and understand why this illness can recur in the liver graft and what are the maternal and fetal outcomes in case of pregnancy after liver transplantation.

FUP180

Proposal and proof of concept analysis for a national Data Infrastructure Platform (stream) for transplantation medicine in Switzerland

Acceptance

Investigator

Michael Koller

Project summary

Background

The Swiss Transplant Cohort Study (STCS) is the nationwide prospective cohort of all solid organ transplant (SOT) recipients transplanted in Switzerland. The STCS longitudinally follows SOT recipients since May 2008 and enrolled around 6200 patients until mid 2021. The STCS is acknowledged as an important player in transplant outcome research. Since the productive start of the STCS in 2008, the focus of the STCS has been on the recipient, starting with transplantation, and the post-transplant period. Therefore, all the reporting activities and the vast majority of the scientific projects involved the mentioned observation period. Although the STCS has created a very potent infrastructure, the existing STCS data infrastructure does not yet systematically link donor-related organ data, organ acceptance and refusal processes, or patient waiting list processes such as selection processes for waiting list acceptance. With the transformation of the STCS from an SNSF longitudinal study into a research-oriented Data Infrastructure and Service (DIS) of national importance, a comprehensive data infrastructure shall be established that integrates all important sources and data providers of the entire solid organ transplantation data ecosystem. The proposed STCS project is envisioned as a longer-term STCS project that involves two main aspects, namely the set-up of the new technical Data Infrastructure Platform (DIP) and a proof-of-concept scientific project that demonstrates the usefulness of the DIP and that serves as a hypotheses generating project of the new and enlarged data infrastructure.

Study aims

Aim 1 (part 1): Build and validate a clinical data warehouse technical infrastructure integrating the candidate waiting list population (SOAS), the donor registry (SOAS), and the transplantation /-post-transplant follow-up period (STCS) and potentially enrich the integrated dataset with patient data from the transplant centers (via IDEAL linkage database and hospital clinical data warehouse). Host the STCS DIP within the secured SPHN BioMedIT node sciCORE next or within the STCS tenant. Aim 2 (part 2): Perform descriptive analyses of the integrated datasets for the main organ transplantation programs in Switzerland, using the time point of waitlisting as the general starting point for all subjects until end of STCS follow-up • Descriptive population characteristics for the different dynamic waitlist and STCS populations • Continuous analysis of the dynamic population sizes by calendar time and patient flows from waitlist to the STCS population Full Proposal – Version 2021.1 2021.06.25 STCS-Project Nr.: FUP180 8/18 • Multi-state time-to event (survival) analyses for the most important state transitions and competing risks endpoints (de-listing, transplantation, death, …) • Perform international comparisons of overall survival estimates of the key transplant programs The product of this project should be a validated and broadly tested data infrastructure that is available to the transplant research (STCS) community and that systematically solves regulatory aspects and aspects of data source linkage.

Study design

As aim 1 (part 1) is a system engineering and implementation project for the STCS DIP, study design considerations don’t apply. For aim 2 (part 2), the study design is a prospective cohort of interlinked individual cohorts of SOT candidates on the transplant waiting list (SOAS), donor-derived graft data (SOAS or SOLDHR for deceased or living donors, respectively) and the STCS, potentially enriched with routine clinical data (IDEAL, www.ideal-project.ch ). The linked datasets build a data continuum where the observation period starts a time of waitlisting and ends with graft failure, definite drop-out or death of the patient.

Lay summary

For transplant patients

This study has a twofold aim: First, to establish a data infrastructure that integrates the data from several healthcare systems that are of key relevance for transplantation medicine. These data systems involve the Swiss Organ Allocation System (SOAS), the living donor registry (SOL-DHR) and the Swiss Transplant Cohort Study (STCS). By connecting the data of these three distinct systems, we hope to build a large database that allows us to improve the knowledge generation about solid organ transplantation in Switzerland. Second, we plan to perform exhausting descriptive analyses of the interlinked databases in order to show the full picture of solid organ transplantation in Switzerland and to run first scientific analyses of this new infrastructure. The Swiss Transplant Cohort Study (STCS) was founded in 2008 in Switzerland and has by today enrolled more than 6200 patients with solid organ transplantations. The STCS has generated important knowledge about transplantation in Switzerland but has also generated important contributions to research. Although being an important science tool nationally and internationally, the focus of the STCS has been transplantation and the post-transplant followup. Transplantation, however, starts much earlier i.e. starting with waitlisting. Now we plan to enlarge the scope of the STCS to involve the entire process from waitlisting until death, termination of graft function or drop out of patients. This study does not us any biological samples. The aim of this study is primarily to set up the data infrastructure to connect the key data sources mentioned. It provides a system to all interested researchers who plan to assess the success of solid organ transplantation using the “expanded scope” of the new platform. The system moreover offers the larger scope for studies on quality of care in the solid organ transplantation field in Switzerland

Descriptive title

Proposal and proof of concept analysis for a national Data Infrastructure Platform (stream) for transplantation medicine in Switzerland

FUP179

Genome-wide Association Study meta-analyses of STCS Kidney Datasets for the iGeneTRAiN cross-organ meta-analyses

Acceptance

Investigator

Brendan Keating

Project summary

Background

Genetic factors contribute to a wide range of transplant outcomes, from acute rejection and complications of prolonged immunosuppression to allograft failure and mortality. Genetic mismatches at human leukocyte antigen (HLA) genes have been studied extensively as independent predictors of rejection and graft survival. However, rejection can occur even in the setting of complete HLA matching, and it has been estimated that only 1 in 5 graft losses are directly attributable to HLA mismatch. This suggests an important role of additional, yet undefined genetic factors in the determination of immune-related outcomes. Over the past decade, genome-wide association studies (GWAS) has proven utility in shedding light into the genetic underpinning of many complex diseases.. The International Genetics and Translational Research in Transplantation Network (iGeneTRAiN) was set up to aggregate as many well phenotyped transplant studies with existing or pending GWAS datasets.

Study aims

We have performed a GWAS meta-analysis for time to acute rejection and time to graft failure or death across multi-ethnic cohorts of kidney, heart and liver transplant recipients as a collaborative effort by iGeneTRAiN. An organ-specific meta-analysis has been performed to investigate the genetic architecture of acute rejection and graft outcomes over time. The cross-organ meta-analysis will assess intra and cross-organ shared genetic susceptibility factors for the aforementioned outcomes.

Study design

Each participating cohort has performed a GWAS for time to acute rejection and graft failure. GWAS summary statistics of each participating cohort are collected centrally and organ-specific as well as cross-organ meta-analyses performed.

Lay summary

For transplant patients

We aim to investigate the genetic architecture of acute rejection and graft loss or death in solid-organ transplant recipients. We have discovered genetic variants associated with graft outcomes in transplant recipients and we aim to replicate these in the STCS. The proposed study will be the most powerful multi-ethnic meta-analysis of solid-organ transplant recipients to date and will likely inform future risk factors in transplant patients.

FUP178

2021-09-15

Investigating drug-induced Chronic Kidney Disease using a pharmacogenomics approach in a multicentric framework

Completed

FUP177

2020-12-09

Randomised controlled trials to assess approved SARS-CoV-2 vaccines in immunocompromised patients: A master protocol for the set-up of a Swiss Cohorts Based Trial Platform

Completed

Investigator

Heiner Bucher

Project summary

Background

A new highly contagious corona virus SARS-CoV-2 has emerged in late 2019 in Wuhan, China, and caused in a two month period a pandemic with the highest disease burden in elderly and people with pre-existing medical conditions. In a situation with no known therapy against SARS-CoV-2 clinical research in Switzerland was ill-prepared at the beginning of the pandemic for launching clinical trials for the rapid evaluation of investigative drugs with postulated in vitro activities against SARS-CoV-2. Use of routinely collected data for nesting trials into cohort studies with highly standardized data collection systems and platform trials allows for rapid patient recruitment and efficient and cost-saving data collection for the simultaneous evaluation of several treatment options, features which can expedite trial protocol development and trial implementation in an epidemic situation. The advantage of using the existing infrastructure of two well-established cohorts is that eligible patients most urgently at need for vaccines or therapies can be more rapidly identified and recruited to trials during regular cohort visits, or by calls. Due to rigorous follow-up monitoring and collection of high-quality phenotypic data the cohort data can be used to define trial baseline data but also for outcome assessment for those parameters that are routinely collected like for example hospitalisations, pneumonia, or death. The use of highly standardized routinely collected data for conducting intervention trials is a highly efficient and economic approach for trial conduct as exemplified by previous groups. Furthermore, a wellestablished trial platform would allow us to react quickly in case of any future outbreak, meaning that fewer hurdles need to be overcome to implement a clinical trial. At present (December 08 2020) Switzerland has still around 4000 new SARS-CoV2 infections per day. Hospitalisations and deaths due to SARS-CoV-2 are high with 18 hospitalisations per 100`000 inhabitants and 11 per 100’000 deaths and the reproduction rate is still around 1 (https://www.covid19.admin.ch/de/overview/hospitalisationen?detTime=14d). It remains unclear whether the current reproduction rate of SARS-CoV-2 can be further lowered and kept during this winter season. According to the University of Oxford (November 25, 2020, https://www.covid19vaccinetracker.org/) 40 vaccines against SARS-CoV-2 are in clinical evaluation, and of those, 10 vaccines are in phase III (including one non-replicating viral vector, three inactivated vaccines, one LNP-encapsulated mRNA, and one 3 LNP-mRNAs) and 237 candidate vaccines are under preclinical investigation. Two vector based mRNA vaccines by Pfizer/BioNTech and Moderna have been approved December 19, 2020 and January 12, 2021 by Swissmedic and vaccination programs start to be rolled out in Switzerland. The Swiss Federal Government has acquired large stocks of both vaccines. These vaccines and others to come use new vector based vaccine strategies that have never been used in humans. In particular, safety and efficacy data in immune compromised patients is only existing in a very limited amount or not at all. Therefore, it is paramount to compare new emerging vaccines for safety and efficacy in those individuals who are at increased risk of complicated Sars-CoV-2 infection and are likely to have reduced vaccine induced immunity like elderly and immune compromised patients. The here presented revised master protocol describes the set-up of the trial platform which is nested into two cohorts and the annexed first sub-study protocol details the pilot RCT which intends to compare the immune response, clinical effectiveness and safety of the first two in Switzerland approved mRNA vaccines against SarsCov_2 in immunocompromised patients. We had submitted the master protocol of the trial platform December 15, 2020 to the Leitethikkommission EKZN without a sub-study protocol as at that time point no vaccine had achieved market authorisation by Swissmedic in order to start a potential trial in a timely manner. The pilot study will primarily assess the functionality of the trial platform and early immunogenicity, efficacy and safety data. At a later stage, the platform might also be used to enlarge the pilot trial or to develop sub-protocols to deal with patients with no or insufficient immune response to Sars-CoV-2 vaccines.

Study aims

The overall objective is to use existing resources from two established national cohorts (i.e. SHCS and STCS) to build a flexible trial platform and to test this platform in the frame of a randomised pilot trial by comparing induced immunity of the two first vaccines that are licensed in Switzerland to prevent SARS-CoV-2 infections and related complications in immunocompromised patients.

Lay summary

Descriptive title

Are the new bivalent Covid-19 vaccines effective and safe in organ transplant recipients and people living with HIV?

Main goals

With the appearance of new COVID-19 variants (e.g. Delta, Omicron) the available mRNA-vaccines from Moderna and Pfizer became less protective. Therefore, new vaccine types were developed to be able to better protect from these new variants (i.e. so-called bivalent vaccines). Hence, our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination.

Why of interest

Despite a decreasing effect, antibody levels remained high at 6 months. Solid organ transplant recipients, particularly lung transplant recipients, showed lower and delayed immune responses. Out of the 174 participants, 8 had a COVID-19 infection within the 6 months after the vaccination with the new bivalent COVID-19 vaccine. Seven out of 8 breakthrough infections were observed among solid organ transplant recipients (5 lung and 2 kidney recipients). Only few participants reported side effects.

Expected benefit

Bivalent mRNA vaccination was safe and produced a stable immune response. How protective this immune response is considering new variants is not entirely clear and needs to be addressed in future studies.

Publications

A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function

FUP176

2021-02-02

Impact of hygiene counseling on the incidence of community acquired respiratory viral infections in lung transplant recipients

Completed

FUP175

Biliary atresia: Swiss national study, 2005 – 2020

Acceptance

Investigator

None

Project summary

Background

The first biliary atresia (BA) Swiss national study was performed including patients from 1994 to 20041. Since 2008, infants with BA born in Switzerland have been mainly managed in the Geneva University Hospitals, and in 2012 the operative management was agreed to Geneva only, following the decision of the Swiss conference of the cantonal health directors. Further, in 2009, a BA screening programme using a stool color card was initiated in Switzerland2. These changes of policies might have changed – or not - the management and outcome of BA babies.

Study aims

The primary aim of the present mono centric study is to compare Swiss management of BA patients and their short and long-term outcomes between the two periods (1994 – 2004 vs. 2005 – 2020). The secondary aim is to compare outcomes with other recently published national series, to analyze the impact of the stool color card on management and outcomes and finally to seek data for further improvement.

Study design

Data concerning epidemiology, birth weight, gestational age, associated syndromes, age at Kasai hepato-porto-enterostomy, surgical technique, postoperative medical management, clearance of jaundice, survival with native liver, overall survival, need for liver transplantation (LT), age at LT, survival after LT and episodes of cholangitis after the Kasai operation will be included in the data base. Correlations between pre- and post-operative data and outcome will be analyzed. Early outcome will be defined as clearance of jaundice (bilirubin less than 20 μmol/l within 6 months) and late outcome as survival with native liver (end point LT or death) and overall survival (end point death).

Lay summary

FUP174

2021-11-22

Pseudo-randomization of short versus long duration of co-trimoxazole prophylaxis in Solid Organ Transplant Recipients: impact on bacterial infections

Completed

FUP173

Donation-after-circulatory death liver transplantation. Outcome and risk factors for ischemic cholangiopathy in the Swiss setting

Acceptance

FUP172

2021-03-17

Epidemiology of glomerulonephritis in Swiss kidney transplant recipients

Completed

FUP171

Comparison between long survivors and short term failure after lung transplantation

Completed

FUP170

Impact of Pre-Transplant Infection on Graft Survival and Post-Transplant Morbidity in Liver Transplant Recipients

Acceptance

FUP168

2020-12-21

Impact of urinary tract infections within the first-year post-transplant on renal allograft outcomes

Completed

FUP167

Norovirus Infection in Solid Organ Transplant Recipients: Incidence, Outcome and Association with Graft Loss

Acceptance

FUP166

Shifting paradigms regarding the role of nontuberculous mycobacteria in patients with cystic fibrosis advanced lung disease

Acceptance

FUP165

Indications for Lung Transplantation in Less Common Diseases

Completed

FUP164

Etiologies and outcome of super-urgent liver transplantation in Switzerland

Acceptance

FUP163

Revisions of the Swiss Transplantation Allocation System for Kidney Transplantation

Acceptance

FUP162

2020-09-17

Rate of utilization of refused liver grafts and its impact in transplant outcome in Switzerland

Completed

FUP161

Epidemiology and characteristics of Parvovirus B19 infections in the Swiss Transplant Cohort Study

Acceptance

FUP160

Multicentric study of coronavirus disease 2019 (COVID-2019) in Solid Organ Transplant Recipients.

OnHold

FUP159

2020-06-17

Epidemiology, Management and Outcomes of Non-Tuberculous Mycobacteria infections in Transplant Recipients in Europe and America (EMOTE study)

Completed

FUP158

2020-06-17

SARS-CoV-2 infections in Solid Organ Transplant Recipients

Completed

FUP157

2020-05-18

Changes in graft steatosis after liver transplantation: A Retrospective Single-Centre Pilot Study

Completed

FUP156

2020-10-26

Geographic Distribution of Kidney Transplantations in Switzerland and Impact on Socioeconomic Reintegration

Completed

FUP155

Liqued biopsy-based genomic assay to enable non-invasive precision diagnostics and monitoring for post-transplant lymphoproliferative disorders (PTLD)

Acceptance

FUP154

Treatment outcome of cancer under checkpoint inhibitor administration in transplanted patients - case series

Acceptance

FUP153

Trans-national comparison of CMV management of SOT recipients in the MATCH and STCS cohort

Acceptance

FUP152

2023-07-19

Characterization of the geographic influence on liver-disease associated mortality and liver transplantation

Acceptance

FUP151

Busulfan-Cyclophosphamide versus Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation: a Prospective Randomized Trial

Acceptance

FUP150

CMV Resistance in solid organ patients in the STCS

Acceptance

FUP149

2020-05-12

Characterization of the effects of statins in the setting of liver transplantation

Completed

FUP148

Identifying Variability and Immune Escape of BK Polyomavirus in Kidney Transplant Patients by Next Generation Sequencing

Acceptance

FUP147

2020-03-18

Vaccine Preventable Diseases in the Swiss Transplant Cohort: Burden and Impact on Immunization

Completed

FUP146

2019-12-03

Missing-self triggers NK cell-mediated rejection of kidney transplants

Acceptance

FUP145

2021-03-02

Pre-transplant donor specific antibodies – does the HLA locus specificity affect kidney transplant outcome?

Completed

FUP144

2020-11-26

Pre-transplant donor specific antibodies – does the type of kidney donation DBD vs DCD affect the impact of DSA on transplant outcome?

Completed

FUP143

2019-10-21

Outcome of Kidney Transplantation from Very Marginal Donors in Switzerland

Completed

FUP142

2019-09-25

Frequency and determinants of renal allograft loss and poor allograft function in the first year post-transplant

Completed

FUP141

2019-09-25

Indications for liver transplantation in Switzerland: Is there a shift from hepatitis C to non-alcoholic fatty liver disease?

Acceptance

FUP140

2019-06-19

Clinical impact of hypomagnesaemia and polymorphisms of genes related to Mgmetabolism in SOT patients from the STCS

Acceptance

FUP139

2019-06-05

Liver transplantation and overall mortality rates in candidates with and without hepatocellular carcinoma in Switzerland

Completed

FUP138

2019-09-25

Prediction of cardiovascular risk in the Swiss Transplant Cohort Study

Acceptance

FUP137

2019-03-20

Association between primary immunosuppression after KTx in children and adolescents and infectious episodes

Acceptance

FUP136

2019-03-20

mTX: The STCS transplant mHealth interaction, network and disease management platform

Acceptance

FUP135

2019-09-25

Impact of trimethoprim-sulfamethoxazole on engraftment in hematopoietic stem cell transplant recipients

Acceptance

FUP134

2019-03-25

Posaconazole dosing and association with therapeutic drug levels in allogeneic cell transplant recipients

Completed

FUP133

2019-06-19

Epidemiology, management and recurrence risk factors of Clostridioides difficile infection among patients undergoing allogeneic Hematopoietic Cell Transplantation: a retrospective multicenter study in Switzerland

Completed

FUP132

2018-12-05

Safety of intravenously administered cidofovir in hematopoietic cell transplant recipients

Completed

FUP131

Intrahepatic microthrombosis in patients with liver cirrhosis undergoing transplantation

Withdrawn

FUP130

2019-06-19

Cumulative deficit frailty index in cystic fibrosis lung transplant candidates: a retrospective validation study

Completed

FUP129

2018-12-05

Optimal duration of treatment of invasive Pseudomonas aeruginosa pneumonia in hematopoietic cell transplant (HCT) recipients

Completed

FUP128

2018-12-05

Antiviral prophylaxis and PTLD occurence in the STCS

Completed

FUP127

2018-12-05

Central Nervous System infections in Solid Organ Transplant Recipients

Completed

FUP126

2020-01-03

Role of Endogenous Hydrogen Sulfide in Kidney Transplantation

Completed

FUP125

2019-12-04

Evaluation of EBV-specific cell mediated immunity (EBV-CMI) for the prediction of posttransplant lymphoproliferative disorder (PTLD) in solid-organ transplant recipients

Acceptance

FUP124

2018-06-20

Genetic mechanisms of rejection and survival after heart transplantation

Acceptance

FUP123

2018-06-20

Characteristics and risk factors for bacteraemia during the first year after solid organ transplantation

Completed

FUP122

2018-06-20

Genome-wide association studies to determinate polymorphisms impacting Hepatic Cell Carcinoma

Acceptance

FUP121

2018-09-19

Evolution of cardiomyopathies after renal transplant

Acceptance

FUP120

2018-06-20

Characterization of differences in infectious disease events between first transplant and re-transplantation of identical organs in the STCS

Completed

FUP119

2018-06-20

Validation of the diagnostic performance of an EBV DNAemia to predict PTLD among transplant recipients

Completed

FUP118

2018-03-21

The Relevance of Pretransplant Iron deficiency for All Cause Mortality andMaximal Exercise Capacity at 1–Year After Heart Transplantation

Acceptance

FUP117

2018-01-15

The STCS - MATCH project: An inter-cohort collaboration between Switzerland and Denmark in transplant outcome research

Acceptance

FUP116

2017-12-06

Comparison of Induction therapy with IL2RA in primary renal transplantations with standard immunological risk versus no induction

Completed

FUP115

2017-12-06

Incidence and risk factors for infection in thoracic-organ transplant recipients on post-transplant extracorporeal membrane oxygenation (ECMO)

Acceptance

FUP114

2017-12-06

Influence of HLA-E genotype on the occurrence of herpesvirus infections and outcome in solid organ transplant recipients in the Swiss Transplant Cohort Study Association between HLA-E genotype and herpesvirus infections in the STCS

Completed

FUP113

2017-12-06

Epidemiology and Outcomes of Microbiologically Documented Bacterial Foodborne Infections in the Swiss Transplant Cohort Study

Completed

FUP112

2017-12-06

Hepatitis E virus seroprevalence and incidence in solid organ and hematopoietic stem cell transplant recipients

Acceptance

FUP111

2017-09-20

CMV_IGRA_Spain_Study

Acceptance

FUP110

2017-09-20

Reducing the Burden of Influenza after Solid-Organ Transplantation: the STOP-FLU trial

Completed

FUP109

2017-06-21

Posttransplant recurrence of membranous nephropathy in Swiss kidney transplant recipients and correlation with clinical and serological markers

Acceptance

FUP108

2017-06-21

The risk of urinary tract infection in different immunosuppressive regimen after renal transplantation in the Swiss Transplant Cohort Study

Stopped

FUP107

2017-12-13

Use and impact of induction therapy in pediatric heart transplantation

Completed

FUP106

2017-06-21

Genetic Variants in TNF Superfamily Genes in the Susceptibility for Chronic Allograft Nephropathy after Transplantation

Acceptance

FUP105

2017-06-21

Influence of screening for tuberculosis on tuberculosis incidence after organ transplantation in regions of tuberculosis incidence of <40/100000

Acceptance

FUP104

2017-06-21

What matters to me: Patient involvement in clinical research within the STCS

Completed

FUP103

2017-06-21

A multicenter retropsective review of outcomes after VRE infections with daptomycin MIC >4 and 2-4 compared to daptomycin susceptible VRE infections in adult abdominal solid organ transplant recipients

Acceptance

FUP102

2017-06-21

Genome-wide association study (GWAS) of single nucleotide polymorphisms in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation

Acceptance

FUP100

2017-06-21

Reconstitution of T cell immunity against cytomegalovirus (CMV) following allogeneic hematopoietic cell transplantation (HCT)

Acceptance

FUP099

2016-09-21

Preformed donor-specific antibodies and liver transplantation

Acceptance

FUP098

2017-06-12

Atopy, a hallmark for Th2 responses in kidney transplantation?

Completed

FUP097

2016-09-21

Lymph vessel density in skin squamous-cell carcinoma patients and possible associations with parameters of immune responses

Acceptance

FUP096

2016-09-21

Passive IgE transfer and allergy development after solid organ transplantation

Completed

FUP095

2017-01-14

Infections in AB0-Incompatible Kidney Transplant Recipients: An Observational Study by the Swiss Transplant Cohort.

Completed

FUP094

2016-06-22

UMOD gene variants and urinary tract infections after kidney transplantation

Acceptance

FUP093

2016-06-22

Impact of Respiratory Virus Infections in Solid-Organ Transplant Recipients

Completed

FUP092

2016-09-21

Novel Memory B Cell ELISPOT Assays to Predict Immune Responses in Renal Allograft Recipients Transplanted Across Donor-specific HLA Antibodies

Completed

FUP091

2016-06-22

Clinical spectrum of lethal infections after solid organ transplantation

Acceptance

FUP090

2016-03-23

Efficacy and safety of different antimicrobials in BSI due to ESBL or carbapenemase-producing Enterobacteriaceae in SOT

Completed

FUP089

Impact of Renal Transplantation on Levels of Cardiovascular Biomarkers and their Prognostic Importance

Stopped

FUP088

2017-06-12

Retrospective analysis of the effect of rituximab on the incidence of EBV replication in kidney transplant recipients

Acceptance

FUP087

2016-03-23

Identification of peripheral blood mononuclear cells signatures associated with rejection and graft outcome after kidney transplantation, a longitudinal prospective study

Acceptance

FUP086

2016-03-23

Posttransplant outcome and risk factors for recurrence in Swiss kidney transplant recipients with IgA nephropathy

Completed

FUP085

2015-12-09

Current world expertise in thoracic transplantation in HIV-positive recipients: AST IDCOP study

Completed

FUP084

2015-12-09

Infection in liver transplant recipients > 65 years: AST IDCOP study

Acceptance

FUP083

2015-12-09

Prospective analysis of 100-days clinical outcome in HSCT engrafted patients with a respiratory virus infection

Withdrawn

FUP082

2015-12-09

Microbiologically confirmed infections in the first year following allogeneic HSCT adult transplantation in Switzerland: a cohort study of the STCS

Completed

FUP081

2015-12-09

Changes of mold-specific T cells and NK cells and impact of polymorphisms in T-helper 1 Cytokines and Natural Killer (NK) genes on the Development and Outcome of Invasive Mold Infections in Patients after Allogeneic Hematopoietic Stem Cell Transplantation.

Acceptance

FUP080

2016-09-21

Post-transplantation prognosis of patients transplanted for cirrhosis and refractory ascites

Acceptance

FUP079

2016-03-23

Post-transplant trajectories of lung transplant recipients related to health-related quality of life and psychological distress within the first three years after transplantation.

Completed

FUP078

2015-09-23

How to cope successfully with an organ transplantation – the role of Antonowsky`s Sense of Coherence

Acceptance

FUP077

Obstructive Sleep Apnea after orthotopic heart transplantation - a risk factor fortransplant vasculopathy ?

Stopped

FUP076

BIOKIT Study - Does Bariatric surgery Improve Outcome of KIdney Transplantation

Stopped

FUP075

Impact of donor and recipient PNPLA3 genotype on fibrosis progression in patients with recurrent hepatitis C after liver transplantation: analysis of the Swiss Hepatitis C Cohort Study and of the Swiss Transplant Cohort Study

Stopped

FUP074

2015-06-24

Prevalence of, risk factors for, and outcome of infections caused by multidrug-resistant Enterobacteriaceae in solid organ transplant recipients

Completed

FUP073

2015-06-24

ExplorinG frailty and mild cognitive impairmEnt in adult kidney tRansplant recipients to predict clinicAl, psychosocial and health economic outcomeS: A repeated measures study design nested in a nationwide prospective cohort study

Completed

FUP072

2015-03-25

Psychosocial questionnaire in hematopoietic stem cell transplant patients - association between relationship status and survival, relapse and graft-versus-host disease.

Completed

FUP071

2015-09-23

ExpLoring a genomic basis for Medication Nonadherence in Transplantation: A subanalysis of the Swiss Transplant Cohort Study

Acceptance

FUP070

2014-12-10

Reviewing prevention measures and evaluating the burden of toxoplasmosis in transplant patients in European countries

Acceptance

FUP069

2014-12-10

Host Immunogenetics of Clostridium difficile Infections in Patients from the Swiss Transplant Cohort Study (STCS)

Acceptance

FUP068

2015-06-09

Epidemiology, microbiology and risk factor analysis of surgical site infections following solid organ transplantation in the STCS

Completed

FUP067

2014-09-17

Echinococcus multilocularis infection in solid-organ transplant recipients

Completed

FUP066

2015-06-24

Prognostic capacities of the kidney transplant failure score (KTFS) and complementary biomarkers after living donation

Completed

FUP065

2014-09-17

LILRB1 polymorphisms and susceptibility to CMV infection and disease in the Swiss Transplant Cohort Study (STCS)

Completed

FUP064

2014-09-17

Dialysis after renal graft loss (DAGL) in Switzerland

Completed

FUP063

2015-09-23

Association of viral reactivation and skin cancer in organ transplant recipients

Acceptance

FUP062

2015-09-23

Cancer development in organ transplant recipients

Completed

FUP061

2014-03-19

Impact of ageing on outcomes of solid organ transplantation in elderly transplant recipients

Completed

FUP060

2014-03-19

Outcome following solid organ transplantation in Switzerland: the Swiss Transplant Cohort Study

Acceptance

FUP059

2014-12-10

Immunosuppressive drugs used to treat antibody-mediated rejection in kidney transplant recipients of the Swiss Transplant Cohort Study (STCS)

Completed

FUP058

2014-03-25

Nocardia infection in solid organ transplant recipients: an international case-control study

Completed

FUP056

2014-02-03

Cellular immune responses to BK polyomavirus (BKPyV) predict clearance of BK viremia in kidney-transplant recipient

Completed

FUP055

2014-09-17

Variation of CT-patterns of Pneumocystis jirovecii pneumonia (PCP) in HIV-infected individuals and recipients of solid organ transplants (SOT).

Completed

FUP054

2014-09-17

Asymptomatic bacteriuria in renal transplant recipients, does it need antibiotic treatment?

OnHold

FUP053

2014-03-19

Virological Monitoring of Teno Torque Virus (TTV) to evaluate Immunological Competence during Immunosuppression following Orthotopic Liver Transplantation

Completed

FUP052

2015-04-09

Monitoring of specific cytomegalovirus cell-mediated immunity (CMV-CMI) for optimization of preventive strategies against CMV infection in high-risk solid-organ transplant recipients

Completed

FUP051

2013-12-04

Validation of the “60-5 Criterion” Low Platelet Counts as an Early Predictor of Complications, Graft Survival and Death after Liver Transplantation.

Acceptance

FUP050

2013-09-11

Impact of Different Prophylactic or Treatment Strategies on the Epidemiology of Invasive Fungal Infections in Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Completed

FUP049

2013-09-11

Validation of scoring systems developed from the French DIVAT cohort for the prognosis of transplantation failures among kidney recipients

Completed

FUP048

Hyperlipidaemia management in the Swiss Transplant Cohort

Stopped

FUP047

2013-09-11

CMV-induced changes to NK cell repertoire and function

Completed

FUP045

2014-03-19

Impact of α-herpesviridae infections in solid organ transplant recipients

Completed

FUP044

2013-12-04

Renal Transplantation, Employment and Disability: A Retrospective, observational before-and-after Feasibility Study by the Swiss Transplant Cohort.

Completed

FUP043

2013-06-26

KIR genotype and viral/fungal infections after solid organ transplantation

Completed

FUP042

2013-06-26

Incidence, Risk Factors and Outcomes of Clostridium difficile associated disease in Solid Organ Transplant Recipients in the Swiss Transplant Cohort Study

Completed

FUP041

2014-09-17

The impact of Hyponatremia on allograft function and patient survival after renal transplantation. A prospective cohort study

Completed

FUP040

2013-06-26

Bloodstream infections with multiresistant pathogens in allogeneic Hematopoetic Stem Cell Recipients from the Swiss Transplant Cohort Study

Completed

FUP039

2013-06-26

Hepatitis C Virus evolution and virus-host interactions after orthotopic liver transplantation

Completed

FUP038

2013-09-11

Adrenergic receptor polymorphisms and maximal exercise capacity after orthotopic heart transplantation

Completed

FUP037

2013-03-13

Blockade of the renin-Angiotensin System in vasoplegic syndrome early after heart transplantation

Acceptance

FUP036

2013-08-05

Does Sleep Quality Predict Health Related Quality of Life in Solid Organ Transplant Patients? A Prospective Cohort Study

Completed

FUP035

2014-09-22

Trends in blood pressure control and treatment after solid organ transplant: a longitudinal prospective swiss transplant study

Completed

FUP034

Transplantation in HIV patients: follow-up and outcome in the Swiss HIV and Swiss Transplant Cohort Studies

OnHold

FUP033

2012-11-28

The reciprocal relationship between CMV and graft rejection after solid organ transplantation

Completed

FUP032

2012-09-05

Polymorphisms of pattern recognition receptors in correlation with skin cancer development in organ transplant recipients

Acceptance

FUP031

2012-11-28

Post-Transplant Lymphoproliferative Disorders: The impact of advances in immunosuppressive drugs over the last three decades on the incidence, characteristics and outcome of lymphomas after solid organ transplantation in the Swiss Transplant Cohort Study

Completed

FUP030

2012-12-05

Systems prediction of Chronic Lung Allograft Dysfunction SysCLAD

Completed

FUP029

2012-09-12

Investigation of genetic markers potentially involved in the incidence of metabolic syndrome in the Swiss Transplant Cohort Study (STCS)

Completed

FUP028

2012-03-14

Impact of implantation of ventricular assist device on the incidence of post-transplant infection in heart transplant recipients

Completed

FUP027

2012-03-14

Innate immune determinants of graft outcome after kidney transplantation

Completed

FUP026

2011-11-02

Investigation of Natural Killer and CD4 T cells before and after Liver Transplantation

Acceptance

FUP025

2011-11-02

Highdimensional Statistical Inference Techniques: Statistical support for STCS scientific projects

Stopped

FUP024

2012-04-24

Epidemiology and treatment of osteo-articular infections in the Swiss Transplant Cohort

Completed

FUP023

2012-03-14

Innate and adaptive immune biomarkers and cytomegalovirus posttransplant

Completed

FUP022

2011-11-07

Bacterial Population Dynamics in Lung Transplant Patients

Completed

FUP021

2012-05-30

Evaluation of genomic and proteomic blood biomarkers for diagnosis of heart/kidney allograft rejection

Acceptance

FUP020

2011-07-06

Association of KIR genotype and CMV replication after solid organ transplantation

Completed

FUP019

2012-03-14

Correlation of vitamin D levels and risk of infectious disease complications after solid organ transplantation

Completed

FUP018

2011-07-06

Epidemiology and management of enterococcal infections in patients from the Swiss Transplant Cohort Study (STCS)

Completed

FUP017

2011-07-06

Epidemiology of fungal infection and colonization in solid organ transplant recipients in the Swiss Transplant Cohort Study. A 3 year follow up.

Completed

FUP016

2010-11-17

Return to Work: a long-term follow-up study after solid organ transplantation in Switzerland

Completed

FUP015

2010-11-17

Determinants, Clinical Manifestations and Significance of Late Onset Cytomegalovirus Disease

Completed

FUP014

2011-04-06

Focal Interventions after Organ Transplantation – a Swiss Multicentre Study

Stopped

FUP013

2010-11-17

Efficacy of Valganciclovir in preventing cytomegalovirus (CMV) disease in high-risk liver transplant recipients

Stopped

FUP012

2010-11-17

Pattern Recognition Receptors Polymorphisms and Infection after Organ Transplantation

Completed

FUP011

2010-05-19

Psychosocial profiles of living-donor compared to deceased-donor kidney allograft recipients

Completed

FUP010

2010-05-19

Role of Mannose Binding Lectin polymorphisms on the Incidence and Course of Cytomegalovirus and other Infections.

Acceptance

FUP009

2010-05-19

Safety of low versus standard dose of valganciclovir for cytomegalovirus prophylaxis in solid organ transplant recipients.

Stopped

FUP008

Prospective study of donor-derived infections in solid organ transplant recipients in Switzerland.

OnHold

FUP007

2010-05-19

Skin cancer development in organ transplant recipients.

Completed

FUP006

2009-08-07

Analysis and validation of deregulated metzincins and related genes in kidney transplant patients with interstitial fibrosis and tubular atrophy (IF/TA) as markers for disease classification and progression.

Acceptance

FUP005

2009-09-29

Do selected pre- and post-ransplant sociodemographic, behavioral and psychosocial factors predict short-term clinical outcomes in adult solid organ transplantation receipients? A subanalysis of the the Swiss Transplant Cohort Study

Completed

FUP004

2009-01-14

The Swiss Transplant Cohort Study: Design, rationale and methods

Completed

FUP003

2009-02-24

AA randomized controlled trial comparing intradermal vs. MF59- adjuvanted vs. standard intramuscular trivalent inactivated influenza vaccine in organ transplant recipients

Stopped

FUP002

2009-06-17

The Annual Infectious Diseases Swiss Transplant Cohort Study Report

Completed

FUP001

2009-06-17

Genetic and functional characterization of the natural killer cell immunity after liver transplantation for hepatitis C associated cirrhosis.

Completed